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SUMMARY 
Breast cancer is the most commonly diagnosed cancer among female. Despite 
advances in cancer treatment, breast cancer has contributed to most of female 
cancer death nowadays. Hence searching for biomarker and therapeutic target 
remained as top priority in breast cancer research. Heparan sulfate 6-O 
sulfotransferase 3 (HS6ST3) is a potential target in this regard. HS6ST3 is a 
key regulator of breast cancer phenotypes. Silencing of HS6ST3 was found to 
suppress breast cancer growth, invasion and migration while inducing 
apoptosis. Understanding of underlying mechanism that lead to phenotypic 
changes would be useful to explore alternate route that contribute to breast 
cancer progression. The aim of this study was to identify potential downstream 
molecules of HS6ST3 in human breast cancer. DNA microarray was used in 
HS6ST3-silenced MCF7 breast cancer cell line to assess genome wide 
expression changes. Analyzed data showed that there were 220 upregulated 
genes and 159 downregulated genes with criteria of absolute fold change >2 
and p-value <0.05. Literature review of the list of genes has found that 
silencing of HS6ST3 could potentially activate interferon signalling pathway 
and TRAIL apoptotic pathway. Several upregulated genes (CEACAM1, 
IFNB1, IRF7, NMI, PML, RARRES3, SP100, STAT1 and TNFSF10) were well 
studied to be involved in breast cancer progression. Their transcript expression 
level was measured by RT-qPCR to verify DNA microarray outcome. All of 
them showed comparable transcript level changes. In order to identify novel 
players in breast cancer progression, 2 potential upregulated interferon 
inducible genes SAMD9 and PSMB9 were selected for further study. These 2 
genes have not been studied in breast cancer but previous evidences from 
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other cancer types suggested that they could suppress tumour progression. 
Functional characterization of both genes in breast cancer was carried out. 
This was done by performing phenotypic assays on SAMD9 or PSMB9 
siRNA-mediated gene silenced MCF7. Silencing of SAMD9 was found to 
suppress cell growth, migration and invasion. However silencing of PSMB9 
did not affect cell proliferation. But it was found to suppress cell migration, 
invasion and adhesion against collagen I while increase cell adhesion against 
fibronectin. The results contradicted with hypothesis that both genes have 
tumour suppression capability. As HS6ST3 downstream target, both SAMD9 
and PSMB9 expression were suppressed by HS6ST3 but they were unlikely to 
contribute to phenotypic changes in HS6ST3-silenced breast cancer. Instead 
they might counteract the observed phenotypic changes. Nevertheless both 
SAMD9 and PSMB9 were found to play certain roles in breast cancer 
progression. Further study would be needed to determine their value as 
biomarker or therapeutic target. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Introduction to Breast Cancer 
1.1.1 Anatomy of Breast 
The breast is secondary sexual feature of females. The base of breast extends 
from 2
nd  
or 3
rd
 to 6
th
 rib in the transverse plan and from sternal edge medially 
to the mid axillary line laterally (Standring, 2008). The breast is formed by 
several structures, such as lobules, ducts and lymph nodes, and is filled with 
fatty tissue and connective tissue (Figure 1.1). Breast receives blood supply 
from branches of axillary artery and internal thoracic artery. Lymph vessel in 
the breast helps to collect and carry lymph fluid away. Lymph vessel and 
nodes are part of lymphatic system, playing important role to fight against 
infection. Main function of breast is to produce, store and release milk to feed 
infant. Lactation occurs immediately after pregnancy. Lobules in the 
mammary gland can produce milk that is carried through the ducts to reach the 
nipple. 
1.1.2 Types of Breast Cancer  
Breast cancer is cancer that originates from breast tissue. There are different 
types of breast cancer that are classified based on their tissue of origin. Ductal 
carcinoma in situ (DCIS) is non-invasive breast cancer. Tumour cells in DCIS 
have not spread through ductal wall to surrounding breast tissue. When it has 
started to break through ductal wall and spread to other body parts through 
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lymphatic system and blood stream, it would be diagnosed as invasive ductal 
carcinoma (IDC). Invasive ductal carcinoma is the most commonly diagnosed  
 
Figure 1.1 Anatomy of female breast. 
invasive breast cancer, which comprises 80% of the cases (American Cancer 
Society, 2014). Another commonly diagnosed invasive breast cancer is 
invasive lobular carcinoma that is originated from lobule. There are other less 
common breast cancer such as inflammatory breast cancer, Paget disease of 
nipple and phyllodes tumour (American Cancer Society, 2014).   
 In inflammatory breast cancer, breast looks red and feels warm. Unlike 
its name suggested, it is not caused by inflammation or infection but by cancer 
cells blockage of lymph vessels (Jacobs & Finlayson, 2011). Breast would 
have thick and pitted appearance similar to orange peel. Breast can also 
become larger, firmer, tender or itchy. Paget disease of nipple usually 
associated with DCIS or IDC. Cancer cells spread from duct to skin of nipple 
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and areola. Nipple skin and areola would appear crusted, scaly and red along 
with bleeding and oozing. Patients could also have feeling of burning and 
itching at associated nipple. Another rare phyllodes tumour has leaf like 
pattern. It is a breast stroma tumour and thus it was also named as 
cystosarcoma phyllodes (Jacobs & Finlayson, 2011).   
1.1.3 Epidemiology of Breast Cancer 
In 2012 around the world, there were 1.7 million patients being newly 
diagnosed with breast cancer and 6.3 millions breast cancer patients with 5-
year survival (Ferlay et al., 2013). The actual incidence has increased by 20% 
and mortality has increased by 14% as compared to estimation made in 2008. 
Breast cancer remained as leading cause of death. Applying prediction by 
population forecast with numbers computed by age-specific rate and 
corresponding population for 10 age groups, Singapore is predicted to have 
4024 new breast cancer cases in 2035, a 59.43% increase from 2524 new 
breast cancer cases in 2012. At the same time, mortality is predicted to be 
1216 cases in 2035, a 93.63% increase from 628 cases in 2012.  
 In the context of Singapore, cancer registry has found that incidence 
rate of cancer cases have increased over the years because growth of aging 
population. Among different cancers, breast cancer is the most prominent with 
biggest increase rate over the same period of time (Teo & Soo, 2013). Breast 
cancer remained as the most frequent cancer type being diagnosed among 
Singapore females. (Figure 1.2A). Breast cancer also contributes to highest 
proportion of cancer related deaths (Figure 1.2B). Breast cancer incidence rate 
has increased from 22.6 (1974-1978) to 63.4 (2009-2013). (Figure 1.3A) 
Introduction 
4 
 
Nevertheless, mortality rate is stable over the years with improving 5-year 
survival rate (Figure 1.3B) and age of diagnosis peak in 60-69 age group 
(Figure 1.3C). The cancer risk, incidence and survival rate differ among racial 
and ethnic groups. This indicated roles of biological factors and lifestyle in 
breast cancer (Henderson et al., 2012). Chinese has the highest cancer 
incidence rate, followed by Malay and Indian (National Registry of Diseases 
Office, 2014). Breast cancer is the most frequently diagnosed cancer type 
among females of all ethnic groups. However, proportion of diagnosed cancer 
type being breast cancer is highest in Indian, followed by Malay and Chinese. 
Age standardized rate of each ethnic groups as such: Chinese (64.3), Malay 
(58.7) and Indian (61.4).   
1.1.4 Breast Cancer Symptoms and Signs 
There are certain symptoms and signs on breast that can be detected by breast 
cancer patients before it is being diagnosed. Since early diagnosis is crucial for 
breast cancer better prognosis, female should do breast self examination 
regularly to avoid missing best treatment window. Breast cancer can alter the 
feeling and appearance of patients' affected breast. There could be change in 
breast size and shape (Jacobs & Finlayson, 2011). This swelling or shrinkage 
of breast could cause recent asymmetry of breast. Skin of breast, areola and 
nipple could have changes in appearance and texture, such as becoming scaly, 
red, swollen, or pitted like orange skin (Movva, 2014). Nipple could turn 
slightly inward or inverted with presence of dimpling or ulceration (Movva, 
2014). Tenderness and itchiness of breast or nipple are also noticeable signs 
(Movva, 2014). Besides, lump could be detected in or near breast and armpit 
although it could be non-cancerous (Movva, 2014). Lastly, bloody or clear 
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fluid being discharged from nipple is also compelling breast cancer symptom 
(Jacobs & Finlayson, 2011). 
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Figure 1.2 Most frequent cancer types being diagnosed (A) and cancer deaths 
(B) among Singapore females. (Adapted from National Registry of Diseases 
Office, 2014) 
 
(A) 
(B) 
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Figure 1.3 Top two graphs showed breast cancer age-standardized incidence 
rate (A) and mortality rate (B) in Singapore from 1974 to 2013. Bottom graph 
showed breast cancer age-specific incidence rate (C) from 2009 to 2013. 
(Adapted from National Registry of Diseases Office, 2014) 
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1.1.5 Breast Cancer Screening and Diagnosis 
Breast cancer screening helps to filter out suspected breast cancer patients 
from larger population before further examination. It is important for early 
detection and thus better treatment option for breast cancer patients. Doctor or 
health professionals can perform clinical breast exam to feel breast and under 
the arm area for presence of lumps (National Cancer Institute, 2014). Another 
commonly prescribed screening test is mammography, which is X-ray scan of 
breast. It could detect lumps that are too small to be felt manually (National 
Cancer Institute, 2014). However it is less effective for lump detection in 
young women with denser breast. Dense breast has less fatty tissue that 
appears as white region on X-ray image and mask potential presence of 
tumour which also appeared white. Size of tumour and skill of radiologist can 
also affect the effectiveness of mammography (Jacobs & Finlayson, 2011). 
Ultrasound scanning could be applied for women under age 35 whose breasts 
are too dense or solid for mammography (Breastcancer.org, 2014). Besides, 
magnetic resonance imaging can be prescribed for screening in patients with 
high risk of developing breast cancer (National Cancer Institute, 2014). It used 
magnet and radio waves combined with advanced computer analysis for 
detailed imaging of body internal area.  
 Suspected breast cancer patients of screening would need further 
diagnostic test by performing biopsy. Fine needle aspiration biopsy is among 
the least invasive method (Jacobs & Finlayson, 2011). It used needle and 
syringe to remove cells sample from suspected breast lump. Core needle 
biopsy used thicker needle for removing core of suspected tissue (Jacobs & 
Finlayson, 2011). Surgical biopsy including incisional biopsy and excisional 
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biopsy can help to establish more definite diagnosis. In incisional biopsy, 
surgeon use scalpel to cut through skin of breast and remove pieces of 
suspected tissue (National Cancer Institute, 2014). While in excisional biopsy, 
surgeon would perform operation to remove lump along with marginal normal 
tissue (National Cancer Institute, 2014). Although this method is the most 
invasive and leave scar on breast, it can establish most definite diagnosis 
without false negative. Cells or tissues from suspected lump would be 
examined by pathologist to determine their current state and patient's diagnosis 
of breast cancer.    
1.1.6 Breast Cancer Staging and Grading 
When patient was diagnosed with breast cancer, the stage and grade of breast 
cancer would be determined to aid in prescription of treatment. Staging was 
used to describe extent and severity of breast cancer. It used TNM staging 
system based on tumour size and tumour spread (Edge et al., 2010). T stands 
for tumour which describes the size of tumour. N stands for nodes which 
describe spreading of cancer cells to lymph nodes. M stands for metastasis to 
check if breast cancer had been spread to other parts of body. Patients were 
staged from early stage 0 to late stage IV based on these 3 criteria where later 
stage meant increasing severity of breast cancer (Edge et al., 2010). 
 Tumour grading is indicator of tumour growth and spreading rate. In 
breast cancer, 3 cancer cell characteristics are being assessed which are tubule 
formation, nuclear grade and mitotic grade (Edge et al., 2010). Tubule 
formation is based on the extent of tumour tissue retaining normal breast duct 
structure. Nuclear grade evaluates tumour cells size and the shape of their 
nucleus. Mitotic grade describes presence and number of dividing cells. Each 
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characteristic is scored from 1 (normal) to 3 (abnormal). In low grade tumour 
(G1, score 3-5), tumour cells are well differentiated. In intermediate grade 
tumour (G2, score 6-7), tumour cells are moderately differentiated. While in 
high grade tumour (G3, score 8-9), tumour cells are poorly differentiated. Both 
breast cancer staging and grading are important factors to be considered while 
planning a suitable treatment regime for patients and to determine their disease 
prognosis (Edge et al., 2010). 
1.1.7 Breast Cancer Treatment 
There are different treatment options available for breast cancer patients based 
on current disease state. After confirmed diagnosis of breast cancer, several 
prognostic factors of breast cancer will be evaluated. These included 
menopausal status of patients, cancer staging and grading, presence of 
estrogen receptor (ER) and progesterone receptor (PR), human epidermal 
growth factor receptor 2 (HER2) overexpression or amplification, and 
histologic type (National Cancer Institute, 2014). Besides that, molecular 
profiling such as Oncotype DX and Mammaprint could be done to predict 
patients' susceptibility to breast cancer metastasis (National Cancer Institute, 
2014).   
 Breast cancer can be treated by conventional approaches which are 
surgery, radiotherapy, chemotherapy and hormone therapy (Jacobs & 
Finlayson, 2011). Surgical removal of tumour lump along with surrounding 
normal tissue remained as the only option with chance to cure cancer. 
Depends on the area of breast that will be surgical removed, the operation can 
be categorized as lumpectomy, partial mastectomy, total mastectomy and 
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modified radical mastectomy (National Cancer Institute, 2014). Breast 
reconstruction could be performed in the same operation or later. 
Radiotherapy applied high energy x-ray or other radiation externally or 
internally to kill cancer cells as well as other fast growing normal cells 
(National Cancer Institute, 2014). Radiotherapy after breast surgery can help 
to decrease risk of cancer metastasis. Chemotherapy can kill bulk of cancer 
cells by targeting fast growing nature of cancer cells. Thus it can also cause 
adverse effect by damaging normal fast growing cells. Systematic 
chemotherapy is useful to treat cancer metastasis while regional chemotherapy 
can limit adverse effect to cancer region (Jacobs & Finlayson, 2011). 
Chemotherapy can also be used as neo-adjuvant therapy to shrink tumour size 
before operation to remove it. Hormone therapy can be applied to breast 
cancer patients with presence of ER and PR. Tamoxifen can block estrogen 
activation of ER and reduce cancer growth. Aromatase inhibitor like 
Exemestane can inhibit conversion of androgen to estrogen in post-
menopausal women and thus inhibit activation of ER (Jacobs & Finlayson, 
2011).  
1.1.8 Breast Cancer Prevention 
Breast cancer could be prevented by managing certain contributing factors. 
Prevention included avoiding risk factors while enhancing protective factors 
against breast cancer. There are unmodifiable risk factors such as sex, age, 
inheritance and breast density (National Cancer Institute, 2014). Therefore 
breast cancer prevention emphasizes on other modifiable factors. Modifiable 
risk factors that were identified included prescription of combination hormone 
therapy, exposure to ionizing radiation, obesity and consumption of alcohol 
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(National Cancer Institute, 2014). Protective factors included early pregnancy, 
breast feeding and exercise. Besides that medical intervention could be applied 
for prevention (National Cancer Institute, 2014). Hysterectomy could help to 
reduce breast cancer risk but increase risk of stroke and cardiovascular disease 
(National Cancer Institute, 2014). Prophylactic mastectomy can decrease 90% 
of breast cancer risk and it is suitable for female in high risk of developing 
breast cancer (National Cancer Institute, 2014). Besides that, prescription of 
Selective Estrogen Receptor Modulator (SERM) and aromatase inhibitor has 
been found to be capable in reducing breast cancer incidence in clinical trials 
(Cuzick et al., 2013). Meta-analysis of five clinical trials using tamoxifen, 
raloxifene, arzoxifene and lasofoxifene showed that there was 38% of 
reduction in breast cancer incidence in 10 years follow-up (Cuzick et al., 
2013). Side effects included 34% decrease in vertebral fracture but 
significantly increase in thromboembolic event. Exemestane, an aromatase 
inhibitor, was also tested on post-menopausal women for breast cancer 
prevention (Goss et al., 2011). There was 65% decrease in annual incidence of 
invasive breast cancer and there was no significant difference in adverse event 
occurrence with minimal changes in quality of life (Goss et al., 2011). In 
short, breast cancer risk could be reduced through changing of lifestyle and 
eating habits, avoid smoking which is known to cause cancer, and take 
appropriate medicine to treat precancerous condition.  
1.2 Introduction to Heparan Sulfate  
Cancer progression involved a lot of contributing factors. Suitable cancer 
microenvironment is crucial for cancer growth. In particular, an important 
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component of extracellular 
matrix, gycosaminoglycans 
(GAG) has important role in 
cancer progression due to its 
involvement in cell 
proliferation, cell migration 
and adhesion. Heparan sulfate 
(HS) is a member of 
glycosaminoglycan that 
present ubiquitously on cellular membrane and extracellular matrix. HS 
saccharide chain was constituted of disaccharide repeats of N-acetyl 
glucosamine (GlcNAc) and uronic acid (glucuronic acid [GlcA] or iduronic 
acid [IdoA]). Figure 1.2 showed fully sulfated HS disaccharide repeats. 
Sulfate group could be added at glucosamine and uronic acid. Acetyl group of 
GlcNAc also can be replaced by sulfate. HS is usually attached to a core 
protein as heparan sulfate proteoglycan (HSPG). HS participates in many 
physiological roles including cell proliferation, inflammation, angiogenesis 
and development through interaction with a wide range of signalling 
molecules like growth factors, chemokines, and clotting factors (Shriver et al., 
2012). As such, its deregulation was manifests as numerous diseases and 
developmental defects. The deregulation originates from altered function of 
HS biosynthesis enzymes. For instance, mutation in exostosin 
glycosyltransferase (EXT1 or EXT2) could lead to hereditary multiple 
exostoses, also known as multiple cartilaginous tumours (Lind et al., 1998). 
Ablation of the enzymes causes absence of HS elongation. Besides that, knock 
Figure 1.2 Heparan sulfate disaccharide 
repeat. 
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out of hs6st can cause defect in muscle development and branching 
morphology of the caudal vein of zebra fish and in tracheal formation of 
Drosophila (Habuchi & Kimata, 2010).  
 Heparin has the same disaccharide repeats as HS, but there are some 
distinct features that distinguished it from HS. In specific, HS has lower 
sulfation level along with higher GlcA content. This can result in HS extended 
bent conformation comparing to heparin (Khan et al., 2011). HS also has 
greater frequency in appearance of minor sequence variation as comparison to 
heparin (Shriver et al., 2012). Heparin appeared to be more homogenous due 
to greater sulfation level with IdoA(2S)-GlcNS(6S) be the most common 
disaccharide. Nevertheless, they share some common binding proteins and 
similar functions suggest certain degree of resemblance in binding site 
conformation (Shriver et al., 2012). Thus heparin sometimes was used to 
illustrate HS structure function relationship as well. However minimal binding 
sequence of HS and heparin with FGF2 respectively that were deduced by 
compositional analysis are different (Kreuger et al., 2001). Heparin itself 
cannot be used to substitute for HS study in certain cases.  
 The function of HS depends on its interaction with its binding partners. 
The interaction is related to HS structural characteristics. However, HS 
binding affinity does not necessary correlate with reactivity. For instance, 
HS3ST3A1 can bind to both HS and other non-substrate GAG ligands with 
high binding affinity (Wille et al., 2007). The discrimination is that only HS 
could induce HS3ST3A1 protein oligomerization for subsequent 
sulfotransferase activity. This suggests similar mechanism could be applied to 
other HS ligands as well where reactivity required specific complex formation 
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and induced oligomerization. The structure of HS was dictated by HS-
modifying enzymes during HS biosynthesis through epimerization and 
sulfation. Therefore changes in specific enzyme expression could potentially 
alter HS function and behaviour contributing to cancer progression. 
1.2.1 Heparan Sulfate Biosynthesis 
Similar to other GAG, HS saccharide chain structure is highly diverse. HS that 
were derived from different organs, tissues or developmental stages were 
measurably different in term of disaccharide content, length and sulfation 
pattern (Shi & Zaia, 2009). It was found that shorter HS tend to be more 
sulfated. However there is no pattern detectable in distribution among organs. 
This explains HS heterogeneous roles in physiological function as well as 
disease aetiology. In order to understand structural diversity in HS, we need to 
have better understanding in HS biosynthesis.  
 HS biosynthesis occurs in Golgi compartment and is orchestrated by 
different enzymes ( 
Figure 1.5). HS is synthesized as side chain of proteoglycans. Protein 
component of proteoglycans determines localization of HS to cell surface or 
extracellular matrix. Free HS only present as a result of enzymatic release 
from HSPG. The initiation of HS biosynthesis is by adding of xylose-
galactose-galactose-glucuronic acid tetrasaccharide onto serine residue of 
HSPG core protein. Adding of each residue is mediated by Xylosyltransferase 
(XYLT1 or XYLT2), galactosyltransferase 1, galactosyltransferase 2 and 
glucuronic acid transferase (GlcAT-1) respectively. This is followed by adding 
of a GlcNAc by EXTL-1, EXTL-2 or EXTL-3 (Kreuger & Kjellén, 2012). The 
Introduction 
15 
 
extension of HS is then catalyzed by EXT1 and EXT2 through adding of GlcA 
and GlcNAc dimer. Subsequently, several HS modifying steps are carried out. 
It starts out with N-deacetylation/sulfation on GlcNAc residue. It is continued 
with epimerization of GlcA to IdoA by C5-epimerase. The change in hexose 
chirality provided structural flexibility in HS. A recent study proposed a tree 
structure for HS biosynthesis (Rudd & Yates, 2012). It proposed that HS can 
be separated into two branches based on their disaccharide repeating unit. It 
shows that epimerase is involved in determining characteristics of HS at an 
early point. In addition, 2-O-sulfation on uronic acid and 3-O, 6-O-sulfation 
 
Figure 1.5 Biosynthesis steps of heparan sulfate. Heparan sulfate 
biosynthesis involved sequential modification by different enzymes resulted in 
structural variation and diversity. 
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on glucosamine of HS by O-sulfotransferases provide additional structural 
heterogeneity.  
 Previous study found that site-directed mutagenesis could generate 
chicken Hs2st1 mutants that exhibit different preference of its sulfation 
activity between IdoA and GlcA (Bethea et al., 2008). Although functional 
implication of the HS products was not studied, it suggests that 
sulfotransferase activity has certain degree of substrates specificity and 
modification of HS is not random event. Besides, 6-O sulfate could be 
removed by sulfatase SULF1/2 in extracellular domain. Most HS biosynthesis 
and modifying enzymes have different isomers together with varied 
expression level and substrate specificity. Differential expression of these 
enzymes dictates cellular production of HS species. In Kamimura et al., 
transgenic fly overexpressing different HS modifying enzymes showed that 
their enzymatic activities could be influenced by expression of others HS 
modifying enzymes. Besides that, different combination in overexpression 
could produce distinct HS structure (Kamimura et al., 2011). Likewise, EXT1 
and EXT2 could modulate N-deacetylase/N-sulfotransferase (heparan 
glucosaminyl) 1 (NDST1) expression and HS sulfation (Goodger et al., 2008). 
On the other hand, Sulf1 and/or Sulf2 knockout mice experiment showed 
locally and distinctly altered HS sulfation patterns in several organs 
(Nagamine et al., 2012). These suggested concerted action among HS 
biosynthesis and modifying enzymes in regulating HS structure. Furthermore, 
reactions that catalyzed by these enzymes were non template driven and often 
incomplete (Kreuger & Kjellén, 2012). Unlike nucleic acid and protein 
synthesis, HS is not synthesized according to pre-coded information. The 
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subsequent modifying steps only occur at selected residues of HS with 
variations. This leaded to HS structural heterogeneity along with varying HS 
biosynthesis enzymes expression.  
1.2.2 Heparan Sulfate and Cancer 
HS has potential role in cancer progression due to its involvement in cell 
proliferation, cell migration and adhesion. It has been implicated in various 
cancers by acting as co-receptor and storage depot for growth factors and 
chemokines. For instance, Binding of CXCL14 to HSPG can trigger cancer 
cell proliferation and migration through NFκB signalling (Park et al., 2013). 
HSPG also can function as internalizing receptors for cancer derived exosome 
to carry out functional activity (Christianson et al., 2013). Glypican-3 (GPC3) 
can enhance activity of Wnt3a/β-catenin signalling to promote cell 
proliferation (Gao et al., 2014). This was achieved by GPC3 attracting Wnt to 
cell surface and act as co-receptor. Germ line mutation of EXT1 resulted in 
hereditary multiple exostoses with increase risk of chondrosarcoma and 
osteosarcoma (Ropero et al., 2004). Its underlying cause is blockage of HS 
synthesis by EXT1 mutation.  
 Furthermore, there is epigenetic regulation of HS biosynthesis 
enzymes. Hypermethylation inactivation of EXT1 is common in cancers such 
as leukemia and non-melanoma skin cancer (Ropero et al., 2004). 
Hypermethylation of HS3ST2 has also been found to be independent 
prognostic indicator for overall survival in node-negative stage I and II non-
small cell lung cancer (Hwang et al., 2013). In contrast, overexpression of 
HS3ST3B1 in pancreatic cancer cells could trigger epithelial-mesenchymal 
transition like phenotype while overexpression of HS6ST2 in colorectal cancer 
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associated with poor prognosis (Hatabe et al., 2013; Song et al., 2011). In lung 
cancer, altered HSPG expression pattern has been observed. In particular, non 
small cell lung cancer has decreased syndecan-1 expression while squamous 
cell lung carcinoma showed reduction in native HS (Nackaerts et al., 1997). 
Glypican-1 was strongly expressed in human pancreatic cancer and facilitates 
mitogenic stimulation response by FGF2 and Heparin-binding EGF-like 
growth factor (HB-EGF) (Kleeff et al., 1998). Besides that, high CD44-HS 
expression level was found to be poor prognostic factor for invasive colorectal 
carcinoma patients (Wielenga et al., 2000). In addition, stromal induction of 
syndecan-1 could contribute to pathogenesis of ovarian adenocarcinoma 
(Davies et al., 2004). 
 As such, different HS mimetic has been developed for cancer 
treatment. PI88, a HS mimetic can inhibit heparanase activity and HS 
effectors' functions. Degradation of HS by heparanase is responsible for 
release of growth factors and chemokines that were originally stored by HS. It 
is associated with cell dissemination and metastatic process. As such PI-88 
was able to impair tumour growth by impaired proliferation, angiogenesis and 
increase apoptosis (Joyce et al., 2005). Similarly, PG500, also HS mimetic, 
has improved potency to inhibit angiogenesis and tumour growth compared to 
PI88 (Dredge et al., 2010). PG545, another version of HS mimetic, has found 
to be able to inhibit primary tumour growth and lung metastasis in 4T1 
syngeneic breast carcinoma model and enhanced overall survival (Hammond 
et al., 2012). Antibody can also be used to block HS function. HS20, a 
monoclonal antibody against GPC3, can disrupt GPC3-Wnt3a interaction and 
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thus inhibit Wnt3a/b-catenin signalling (Gao et al., 2014). It has shown anti-
proliferative properties that inhibit hepatocellular carcinoma xenograft growth.  
1.2.3 Role of Heparan Sulfate in Breast Cancer 
This thesis focuses on HS in breast cancer. There are several studies have 
implicated involvement of HS in breast cancer. Stromal HS expression is 
significantly associated with tumour grade, stromal p53 and MIB1 expression 
in proliferating cells of Phyllodes tumours (Koo et al., 2006). Thus HS might 
play a role in malignant tumour growth. HSPG expression level in breast 
cancer was regulated by estrogen receptor, epidermal growth factor receptor 
and Insulin-like growth factor receptor (Tsonis et al., 2013). FGF2 is one of 
most commonly studied growth factor that interacts with HS. FGF2 promote 
growth by formation of FGF-2/HSPG/FGFR-1 complex. Breast cancer has 
increase ability to form the complex compared to normal breast epithelial cells 
(Mundhenke et al., 2002).  
 However not all breast cancer cell lines were responsive to FGF2 
mitogenic effect. MDA-MB-231, an invasive breast cancer cell line with high 
expression of HSPG appears to be resistant to FGF2 growth promoting effect. 
Treatment of MDA-MB-231 with sodium chlorate, metabolic inhibitor of 
proteoglycan sulfation, could result in dose dependent effects. In low dose 
treatment, sodium chlorate can promote FGF2 induced proliferation in MDA-
MB-231 (Delehedde et al., 1996). This could be explained by altered FGF2 
binding site on HS. Sodium chlorate treatment resulted in HS only retained 
binding site with fast association kinetic and high affinity but not binding site 
with slow association kinetic and low affinity (Fernig et al., 2000). In high 
dose, sodium chlorate can abolish the proliferative effect (Delehedde et al., 
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1996). This showed that sulfation level of HS dictate its function. HS can act 
as co-receptor to FGF2 at moderate sulfation level, but capture FGF at higher 
sulfation level. Another study also found that transforming growth factor beta 
(TGF-β) or sodium butyrate can inhibit proliferation of MCF7, MDA-MB-231 
and normal breast epithelial cells by increase incorporation of 35S into HSPG 
(Lambrecht et al., 1998). This increase sulfation resulted in increase FGF2 
binding to HSPG but inhibit proliferation. Thus altered HSPG structure would 
have significant impact on its function and affect breast cancer cell growth 
regulation.  
 SULF2, an extracellular HS sulfate degrading enzyme, is upregulated 
in breast cancer which can promote angiogenesis (Morimoto-Tomita et al., 
2005). HSPG also play certain role in breast cancer treatment. Imatinib, a 
tyrosine kinase inhibitor, can target platelet-derived growth factor (PDGF)-a 
and b in breast cancer and inhibit cell proliferation, invasion, migration and 
cell surface expression of HSPG of breast cancer (Malavaki et al., 2013). 
Furthermore, responsiveness of breast cancer to trastuzumab relies on high 
expression of HER2 as primary target, as well as high level of syndecan-1 and 
HS on cell surface along with low level of secreted HS (Suarez et al., 2013). 
Resistance to trastuzumab can be achieved by adding of anti-HS antibody or 
heparin, or transfection of HPSE1, an enzyme that cleaves HS from HSPG 
(Suarez et al., 2013). Shedding of HS in resistant breast cancer cells might 
responsible to capture trastuzumab and prevent its action. 
 
 
Introduction 
21 
 
1.2.4 Role of Heparan sulfate O-sulfation 
HS epitope mapping by phage display antibodies also found that O-sulfation is 
essential for binding (Thompson et al., 2009). However sulfation level on HS 
does not correlate with reactivity. Although the antibodies could recognize 
distinct epitopes but they are not single linear sequence but families of 
structural similar motifs (Thompson et al., 2009). Additionally, disulfated 
tetrasacharide HS could bind HGF/SF with lack of apparent positional 
requirement for the two sulfation showed certain degree of flexibility in HS-
HGF/SF interaction (Deakin et al., 2009). Besides, stability of FGF/HS/FGFR 
correlated with overall sulfation but not precise distribution of sulfate groups 
(Jastrebova et al., 2006). Sulfation level and pattern on HS are also partly 
dictated by SULF1/2 through 6-O desulfation activity. SULF1/2 desulfation 
activity is relying on domain structure surrounding the target sulfate moiety 
with higher activity at NRE region (Staples et al., 2011). Presence of this 
additional layer of regulation also implies importance of 6-O sulfation at NRE 
on HS function. SULF1/2 target selectivity means that it can affect specific 
signalling pathways through disruption of HS binding. In short, sulfation on 
HS provided necessary surface charge for ionic interaction and contributed to 
conformational specificity for binding.  
 Knock out studies on different HS sulfotransferase imply their 
differential roles on development (Gorsi & Stringer, 2007). For instance, mice 
with Hs6st2 knock out showed abnormal muscle phenotype while Ndst2 knock 
out could impact mast cells differentiation. Therefore, sulfate modifying 
enzymes of HS with different roles, different isoforms with separate 
transcriptional controls served as complex regulating network of HS function. 
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Elucidating this network would be crucial to understand HS function and 
regulation in physiological and disease condition. 
1.3 Heparan Sulfate 6-O Sulfotransferase (HS6ST3) 
Sulfate group on HS saccharide chain is important for HS function. HS6ST3 is 
responsible for adding of sulfate group on HS during biosynthesis process. 
HS6ST3 is an enzyme that localized in Golgi apparatus and performs 6-O 
sulfation. Mouse study has found that HS6ST3 was only expressed at later 
stage of developmental stages (Sedita et al., 2004). Overexpression of 
HS6ST3 in human embryonic kidney 293 cells can alter HS domain structure 
to form extended 6-O sulfated predominantly N-acetylated HS domains (Do et 
al., 2006). Interestingly, HS6ST3 can be secreted although its main function in 
Golgi apparatus.  Mouse HS6ST3 was found to be secreted via β-secretase 
dependent pathway to extracellular domain (Nagai et al., 2007). Human 
HS6ST3 has genetic similarity of 94% as mouse Hs6st3, which indicated that 
human HS6ST3 could have similar properties. The secretion can be blocked 
by silencing of β-secretase (Nagai et al., 2007).  
 HS6ST3 and SULF1 were highly expressed in chondrosarcoma from 
immunohistochemistry analysis of patients' tissue samples (Waaijer et al., 
2012). HS6ST3  has been found to be upregulated  in   breast  cancer  cell  
lines  (T47D,  MCF7,  MDA-MB-231).  Silencing of HS6ST3 can cause 
several phenotypic changes which included decrease of cell proliferation, 
migration and invasion, increase of cell adhesion and induction of apoptosis 
(Iravani, 2011). In immunohistochemistry study, upregulation of HS6ST3 in 
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stromal matrix of ductal carcinoma clinical samples was correlated with poor 
prognosis (Iravani, 2011).  
 Although the mechanisms of heparan sulfate modifications are well 
studied, less is known about how it leads to breast cancer progression. In this 
study, mechanism of HS6ST3 altering breast cancer behaviour is of interest. 
Study of novel breast cancer carcinogenesis pathways would help us have 
better understanding breast cancer to formulate better treatment strategies. In 
order to identify signalling pathway downstream of HS6ST3, RNA samples of 
HS6ST3 silenced MCF7 were sent for microarray analysis to detect global 
gene expression changes. Results showed that once HS6ST3 was silenced in 
MCF7, 220 genes were upregulated while 159 genes were downregulated. 
Upon sorting through the list of genes, several prominent potential signalling 
pathways have been identified; among them are interferon signalling pathway 
and antigen presentation pathway. As such, two potential upregulated 
downstream targets involving those two pathways were selected, which are 
Sterile Alpha Motif Domain containing 9 (SAMD9) and Proteasome (prosome, 
macropain) subunit, beta type, 9 (PSMB9). Although these two genes have 
been implicated to be deregulated in other cancers, they have no known role in 
breast cancer (Ma et al., 2014; Hayashi et al., 2006). Therefore it is of interest 
to study their possible roles in breast cancer.  
1.6 Aim of Study 
Understanding of underlying mechanism about how HS6ST3 regulate human 
breast cancer progression is of great interest. Therefore, the objective of this 
study was to identify potential downstream molecules of HS6ST3 in human 
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breast cancer. The study also aimed to identify novel target related to HS6ST3 
that could play certain role in human breast cancer. 
1.7 Hypothesis 
SAMD9 and PSMB9 were identified as novel target that have not been studied 
in breast cancer. First hypothesis was that SAMD9 could exert tumour 
suppression effect in human breast cancer. Second hypothesis was that 
PSMB9 could exert tumour suppression effect in human breast cancer. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Cell Culture 
All cell culture work was performed in Biological Safety Cabinet Class II. 
Several human normal breast epithelial and cancer cell lines that has been used 
for experiments included MCF7, T47D and MDA-MB-231 (American Type 
Culture Collection, Manassas, Virginia, USA) . All cell lines were cultured in 
CO2 incubator at 37°C, 5% CO2. MCF7 was maintain in DMEM (Dulbecco's 
Modified Eagle Medium) (Hyclone
TM
, GE Healthcare, Logan, Utah, USA) 
with 10% Fetal Bovine Serum (FBS) (Hyclone
TM
, GE Healthcare,). T47D and 
MDA-MB-231 were maintained in RPMI (Roswell Park Memorial Institute 
medium) (Hyclone
TM
, GE Healthcare) with 10% FBS.   
2.1.1 Thawing of human normal breast epithelial and cancer cells 
Cryovial preserved frozen cells was removed from nitrogen tank. Frozen cells 
in cryovial were thawed in 37°C water bath immediately. Thawed cells were 
transferred to 15ml tube. 4ml of complete culture medium (with added FBS) 
was added into the tube and mixed by pipetting. Cells were centrifuged for 5 
minutes at 162×g to form cell pellet. After centrifugation, supernatant in the 
tube was removed and cell pellet was resuspended in 4ml of complete culture 
medium. Cell suspension was transferred to a T25 flask and maintained in 
CO2 incubator.  
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2.1.2 Subculture of human normal breast epithelial and cancer cells  
When cell culture in flask reached around 70% cell confluency, cells were 
trypsinized and subcultured into new flask. Culture medium in flask with 
growing cells was removed. Cell culture was washed with 1× phosphate 
buffered saline (PBS). In cases of MCF7, T47D and MDA-MB-231, 1× 
Trypsin-EDTA was added into the flask. The flask was incubated in CO2 
incubator for 5 minutes for trypsinization to take place. After cells were 
detached from surface, equal volume of complete culture medium was added 
in to inactivate trypsinization. Cell suspension was transferred to 15ml tube 
and centrifuged for 5 minutes at 162×g. Supernatant was removed from the 
tube and the remaining cell pellet was resuspended with fresh complete culture 
medium. Cell suspension was transferred to a new flask and maintained in 
CO2 incubator at 37°C, 5% CO2.  
2.1.3 Cryopreservation of human normal breast epithelial and cancer 
cells 
Cells growing in flask were collected in cell suspension as described above in 
subculture of cells. 10% of dimethyl sulfoxide (DMSO) was added into the 
cell suspension in drop wise with shaking. The resulting DMSO-containing 
cell suspension was aliquoted into cryovials, 1ml each. The cryovials with cell 
suspension were kept in Mr. Frosty™ Freezing Container and gradually frozen 
in -80°C freezer. 24 hours later, the cryovials were transferred and stored in 
liquid nitrogen tank for long term storage.  
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2.2 Gene Silencing 
Gene silencing was done through transfection of siRNA (Ambion, Carlsbad, 
CA, USA). HS6ST3, PSMB9 and SAMD9 were silenced in MCF7 and T47D 
under different optimized condition to achieve the best silencing efficiency.  
Table 2.1 List of siRNA for gene silencing. 
Gene (Working 
Concentration) 
siRNA ID Sequence (5' → 3') 
HS6ST3 
(100nM) 
40347 
Sense GGAAGACACAGUUUCUCUUtt 
Antisense AAGAGAAACUGUGUCUUCCtc 
SAMD9 
(5nM) 
s29485 (S2) 
Sense GCUCUAAGGACAUUACGAAtt 
Antisense UUCGUAAUGUCCUUAGAGCtg 
s500025 (S4) 
Sense GAACCGUCAGGAAUACGUAtt 
Antisense UACGUAUUCCUGACGGUUCat 
PSMB9 
(10nM) 
s11365 (S1) 
Sense GCACCUUUAUCUAUGGUUAtt 
Antisense UAACCAUAGAUAAAGGUGCtg 
s11366 (S2) 
Sense GGAGGUCAGGUAUAUGGAAtt 
Antisense UUCCAUAUACCUGACCUCCtt 
 
2.2.1 HS6ST3 silencing in MCF7 
MCF7 was seeded at cell density of 2×10^5 per well in 6 well plate. 24 hours 
after seeding, transfection was performed. First there is preparation of Mixture 
A (180μl OptiMEM (Life Technologies, Carlsbad, CA, USA)) + 5μl 20μM 
siRNA) and Mixture B (10μl OptiMEM + 5μl Oligofectamine (Life 
Technologies). This is followed by incubation time of 5 minutes. Afterward, 
Mixture A and Mixture B was mixed together to facilitate formation of siRNA 
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oligofectamine complexes. This step required 20 minutes of incubation time. 
In the meanwhile, culture medium in 6 well plate with cells seeded was 
replaced with 800μl OptiMEM. After incubation time of 20 minutes, 200μl of 
siRNA transfection mixture was added onto seeded cells. After gently shaking, 
cells were allowed to grow in incubator at 37C 5% CO2 for 8 hours. 
Subsequently, 500μl of DMEM with 30% FBS was added into each well of 
transfected cells to inactivate transfection. At post transfection 24 hours, 
transfected cells was replaced with 2ml fresh DMEM with 10% FBS. At 48 
hours post transfection, the transfected cells were ready for use in RNA 
extraction, protein extraction and phenotypic assays.  
2.2.2 SAMD9 silencing in MCF7 
MCF7 was seeded at cell density of 1×10^5 per well in 6 well plate. 24 hours 
after seeding, transfection was performed. First there is preparation of Mixture 
A (180μl OptiMEM + 5μl 1μM siRNA) and Mixture B (10μl OptiMEM + 5μl 
Oligofectamine). This is followed by incubation time of 5 minutes. Afterward, 
Mixture A and Mixture B was mixed together to facilitate formation of siRNA 
oligofectamine complexes. This step required 20 minutes of incubation time. 
In the meanwhile, culture medium in 6 well plate with cells seeded was 
replaced with 800μl OptiMEM. After incubation time of 20 minutes, 200μl of 
siRNA transfection mixture was added onto seeded cells. After gently shaking, 
cells were allowed to grow in incubator at 37C 5% CO2 for 8 hours. 
Subsequently, 500μl of DMEM with 30% FBS was added into each well of 
transfected cells to inactivate transfection. At post transfection 24 hours, 
transfected cells was replaced with 2ml fresh DMEM with 10% FBS. At 48 
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hours post transfection, the transfected cells were ready for use in RNA 
extraction, protein extraction and phenotypic assays. 
2.2.3 PSMB9 silencing in MCF7 
MCF7 was seeded at cell density of 1×10^5 per well in 6 well plate. 24 hours 
after seeding, transfection was performed. First there is preparation of Mixture 
A (175μl OptiMEM + 10μl 1μM siRNA) and Mixture B (10μl OptiMEM + 
5μl Oligofectamine). This is followed by incubation time of 5 minutes. 
Afterward, Mixture A and Mixture B was mixed together to facilitate 
formation of siRNA oligofectamine complexes. This step required 20 minutes 
of incubation time. In the meanwhile, culture medium in 6 well plate with 
cells seeded was replaced with 800μl OptiMEM. After incubation time of 20 
minutes, 200μl of siRNA transfection mixture was added onto seeded cells. 
After gently shaking, cells were allowed to grow in incubator at 37C 5% CO2 
for 8 hours. Subsequently, 500μl of DMEM with 30% FBS was added into 
each well of transfected cells to inactivate transfection. At 48 hours post 
transfection, the transfected cells were ready for use in RNA extraction, 
protein extraction and phenotypic assays.  
2.3 Total RNA Extraction  
Total RNA of cells growing on 6-well plate was extracted using Direct-zol™ 
RNA MiniPrep kit (Zymo Research, Irvine, CA, USA) according to 
manufacturer protocol. Cells were washed with 1× PBS once. Monolayer cells 
were lysed with 950μl TRI-reagent® for 5 minutes. Lysate was collected and 
centrifuged at 12,000×g for 1 minute. Supernatant was transferred to a new 
tube and mixed with 950μl of 100% Ethanol. The resulting mixture was 
Materials and Methods 
30 
 
subjected to flow through Zymo-Spin
TM
 IIC Column for RNA binding by 
centrifugation at 12,000×g for 1 minute. This was followed by washing step of 
400μl Direct-zolTM RNA Prewash twice and 700μl RNA wash buffer once. All 
washing steps were done by centrifugation at 12,000×g for 1 minute. 
Nuclease-free H2O was used to elute RNA from spin column. 32μl of 
nuclease-free H2O was added into spin column and incubated for 1 minute. 
Total RNA was eluted into new Eppendorf tube by centrifugation at 12,000×g 
for 1 minute. Concentration (ng/μl) and purity of RNA (260/280 ratio) were 
measured by NanoDrop 1000 spectrophotometer (Thermo Scientific, Waltham, 
MA, USA). 
2.4 Synthesis of First Strand cDNA  
Total RNA has to be converted into cDNA for subsequent RT-qPCR. cDNA 
conversion was done using SuperScript
TM
 III Reverse Transcriptase (Life 
Technologies) according to manufacturer protocol. 2μg of total RNA was 
converted into cDNA for each reaction. Mixture A consisting of total RNA, 
dNTP mix (Promega), random hexamer and nuclease-free H2O (top up to 
11μl) was prepared and heated at 65°C for 5 minutes. This was followed by 
incubation on ice for 3 minutes. Mixture B consisting of SuperScript
TM
 III 
Reverse Transcriptase, RNasin
® 
Plus RNase Inhibitor (Promega, Madison, WI, 
USA), 0.1M dithiothreitol (DTT) and 5× First-Strand buffer was added into 
Mixture A and mixed by gentle pipetting. Subsequently, the reaction mixture 
was incubated at 25°C for 5 minutes. This was followed by cDNA conversion 
step with incubation at 50°C for 1 hour. The reaction was inactivated by 
heating at 70°C for 15 minutes. Converted cDNA was stored in -20°C. 
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2.5 Polymerase Chain Reaction (PCR) 
PCR was used to amplify gene product or primers amplicon. It was used to 
determine presence of target gene and primer specificity. Taq PCR Core kit 
(Qiagen, Venlo, Limburg, Netherlands) was used, a PCR reaction (20μl) 
comprised 2μl 10× Buffer, 4μl Q solution, 0.4μl dNTP, 2μl forward and 
reverse primers, 0.1μl Taq polymerase, DNA or bacteria, and H2O (top up to 
20μl).  PCR reaction was run on thermal cycler with protocol as described 
below (Table 2.2). 
Table 2.2 PCR amplification protocol. 
Steps Description Duration Temperature (°C) Cycles 
Polymerase activation and 
DNA denaturation 
3 mins 94 1 
Amplification Steps    
Denaturation 30 sec 94 
35 Annealing 30 sec 60 
Extension 1 min 72 
Final Extension 10 mins 72 1 
 
2.6 DNA Gel Electrophoresis 
DNA gel electrophoresis was used to separate DNA PCR product. 1.5% gel 
was prepared by mixing 0.9g agarose in 60ml 1× Tris-acetate-EDTA (TAE) 
buffer. It was heated until agarose fully dissolved. When the agarose solution 
cool down, 1.2μl of ethidium bromide was added in and it was poured into gel 
casting tray. A comb was inserted on top of the tray immediately and presence 
of any bubble was removed. DNA sample was mixed with 6× loading dye 
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(Fermentas, Carlsbad, CA, USA). When agarose gel has solidified, comb was 
removed and the gel was put into electrophoresis chamber connected with 
power supply. DNA sample was loaded into each well. The gel electrophoresis 
was run with constant voltage of 90V for 45 minutes. When the run was 
completed, gel was viewed under UV illuminator of ChemiDoc MP System 
(Bio-Rad, Hercules, CA, USA).  
2.7 Reverse Transcription - real-time quantitative Polymerase 
Chain Reaction (RT-qPCR)  
One-step and two-step RT-qPCR methods have been used to determined gene 
transcript level. One-step RT-qPCR combined both cDNA conversion and RT-
qPCR in a single reaction and use total RNA as starting material. It was done 
by iTaq™ Universal SYBR® Green One-Step Kit (Bio-Rad). Reaction 
mixture of 2x iTaq universal SYBR
® 
Green reaction mix (5μl), iScript reverse 
transcriptase (0.125μl), 10μM forward and reverse primers (0.6μl), total RNA 
(100ng) and nuclease-free H2O (top up to 10μl) was prepared and run in 
CFX96 Real-Time PCR Machine (Bio-Rad) with protocol below (Table 2.3). 
Table 2.3 One step RT-qPCR amplification protocol. 
Steps Description Duration Temperature (°C) Cycles 
Reverse Transcription reaction 10 mins 50 1 
Polymerase activation and  
DNA denaturation 
1 min 95 1 
Amplification Steps     
Denaturation 10 sec 95 
40 
Annealing/ Extension 
with plate read 
30 sec 60 
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Melt Curve Analysis 65°C-95°C with 0.2°C increment 
 
Two step RT-qPCR use cDNA as starting material for gene amplification and 
transcript signal detection. This was done by SssoAdvanced Universal SYBR 
Green Supermix (Bio-Rad). Reaction mixture of 2× SsoAdvanced universal 
SYBR
®
 Green supermix (5μl), 10μM forward and reverse primers (1μl), 
cDNA (10ng) and nuclease-free H2O (top up to 10μl) was prepared and run in 
CFX96 Real-Time PCR Machine (Bio-Rad) with protocol below (Table 2.4). 
Table 2.4 Two step RT-qPCR amplification protocol. 
Steps Description Duration Temperature (°C) Cycles 
Polymerase activation and  
DNA denaturation 
30 sec 95 1 
Amplification Steps     
Denaturation 10 sec 95 
40 
Annealing/ Extension 
with plate read 
30 sec 60 
Melt Curve Analysis 65°C-95°C with 0.2°C increment 
  
Table 2.5 List of primers for PCR. 
Gene 
Symbol 
Forward Primer Reverse Primer 
Product 
Size 
(bp) 
ACTB TGGCACCACACCTTCTACAAT GATAGCACAGCCTGGATAGCA 166 
CEACAM1 ACAGGAGGAAGACAGGCAAA CCTCCTGGAGAAAGCCTCTT 136 
GAPDH GAAGGTGAAGGTCGGAGTCAACG TGCCATGGGTGGAATCATATTGG 158 
HS6ST3 CATCTCCCCCTTCACACAGT CTCGTAAAGCTGCATGTCCA 112 
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IFNB1 TCTCCTCCAAATTGCTCTCC TGCTGCAGCTGCTTAATCTC 195 
IRF7 ACTGTGACACCCCCATCTTC CAGGGAAGACACACCCTCAC 224 
NMI GTTACGGCCAAGCCAGTTC CTTGTCAGCCACTCCAATCTC 243 
PML GGAGCAGGATAGTGCCTTTG CTGGCCATCTCCTCGTAGTC 198 
PSMB9 GACGGGGGCGTTGTGATGGG TCCAGCTGGTAGGCGGCCAT 167 
RARRES3 GTGAGCAGGAACTGTGAGCA CAAAAGAGCATCCAGCAACA 136 
SAMD9 AGCCGAGTAGCAAACCTTCA ACCTGCCATTGCAGAAAATC 121 
SP100 CAACAGAGTCCTGCGAACAA TATCCACCAGTCGCACAGAA 156 
STAT1 CAATGGTGTGGCAAAGAGTG GGGCATTCTGGGTAAGTTCA 140 
TNFSF10 GCAAGTCAAGTGGCAACTCC TGTGTTGCTTCTTCCTCTGG 172 
 
2.8 Protein Extraction and Quantification 
Protein was extracted from cells growing in 6-well plate format. Cell lysis 
buffer was prepared by mixing M-PER Mammalian Protein Extraction 
Reagent (Thermo Scientific, Carlsbad, CA, USA), Halt Protease Inhibitor 
cocktail and 0.5M EDTA solution in ratio 100:1:1. Cells were washed with ice 
cold 1× PBS twice. A total 204μl of cell lysis buffer was added into each well 
of 6-well plate and incubated on ice for 5 minutes with shaking. Cell scrapper 
was used to detached cells from 6-well plate and resulting cell lysate was 
transferred to an Eppendorf tube. Cell lysate was subjected to centrifugation at 
12,000×g for 10 minutes. Protein supernatant was transferred to new tube and 
stored in -80°C.  BCA Protein Assay kit (Pierce, Waltham, MA, USA) was 
used to quantify protein concentration.  Protein standards were constructed by 
preparation of bovine serum albumin (BSA) solution in subsequent 
concentrations: 2000μg/ml, 1500μg/ml, 1000μg/ml, 750μg/ml, 500μg/ml, 
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250μg/ml, 125μg/ml, 25μg/ml and a blank. 10× dilution of sample protein 
intended to be measured was prepared. BCA reagent was prepared by mixing 
BCA reagent A and BCA reagent B in 50:1 ratio. 25μl of standard BSA 
protein solution and sample protein were added into 96-well plate. 200μl of 
BCA reagent was added into each well with protein. Plate was shook for 30 
seconds and incubated for 30minute at 37°C. After incubation, plate was 
cooled down to room temperature for 5 minutes. Absorbance at 562nm of each 
well was measured on spectrophotometer plate reader. 
2.9Western Blot 
2.9.1 Sodium Dodecyl Sulfate (SDS) Gel Preparation 
Glass plate and 1.5mm spacer plate were wiped with 70% ethanol prior to 
assembly. They were assembled into glass cassette sandwich for gel 
formation. 10ml resolving gel solution was prepared for a SDS gel. It was 
consisted of  4ml H2O, 3.3ml 30% Acrylamide/Bis solution (Bio-Rad, 
Hercules, CA, USA), 2.5ml 1.5M Tris (pH8.8), 100μl 10% SDS, 100μl 10% 
ammonium persulfate (APS) and 4μl TEMED.  7ml Resolving gel solution 
was poured into the glass cassette sandwich immediately after adding of 
TEMED. 1ml of isopropanol was added on top of the resolving gel solution to 
seal off air contact. Stacking gel solution was prepared while waiting for 
resolving gel to solidify. 5ml of stacking gel solution consisting of 3.4ml H2O, 
830μl 30% Acrylamide/Bis solution (Bio-Rad), 630μl 1.0M Tris (pH6.8), 50μl 
10% SDS and 50μl 10% APS. When resolving gel was solidified, upper layer 
of isopropanol was poured away. 5μl of TEMED was added into stacking gel 
solution and the mixture was poured on top of resolving gel. Plastic comb was 
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inserted into glass cassette sandwich immediately and avoid any bubble 
formation. 
2.9.2 Protein Preparation 
20μg of protein from each sample was prepared for western blot. Protein was 
mixed with 5× SDS loading dye. It was heated for 3 minutes at 95°C for 
protein denaturation. 
2.9.3 Gel Electrophoresis 
After stacking gel was solidified, comb was removed carefully. Gel cassette 
was hold in place in electrophoresis chamber. The electrophoresis chamber 
was filled with 1× Tris/ Glycine/ SDS buffer. Proteins were loaded into 
separate wells of the gel. The electrophoresis chamber was connected to 
powerpac for power supply. It was run with constant voltage of 50V for 30 
minutes for protein to migrate through stacking gel and was switched to 
constant voltage of 100V for 90 minutes for remaining run through resolving 
gel. 
2.9.4 Protein Semi-Dry Transfer 
When gel electrophoresis was completed, SDS gel was removed from glass 
cassette and equilibrated in transfer buffer (1× Tris/Glycine buffer (Bio-Rad) 
with 20% methanol) for 10 minutes. Appropriate size of polyvinylidene 
difluoride (PVDF) membrane was soaked in methanol for 30 seconds 
activation and followed by washing in H2O for 2 minutes. It was then 
equilibrated in transfer buffer for 10 minutes with shaking. 2 pieces of thick 
filter papers were soaked in transfer buffer prior to assembly of gel-membrane 
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sandwich. After equilibration step, gel-membrane sandwich was assembled 
with order of filter paper, PVDF membrane, SDS gel and filter paper from 
bottom to top. Roller was used to removed any bubble existed in gel-
membrane sandwich. Trans-Blot
®  
Turbo
TM
 system (Bio-Rad) was used to 
perform semi-dry transfer. It was run on constant voltage of 1.5V for 45 
minutes. 
2.9.5 PVDF Membrane Blotting 
After protein transfer was completed, PVDF membrane was blocked in 5% 
milk in 0.1% tris buffered saline with 0.1% Tween
®
 20 (TBST) for 1 hour at 
room temperature. Afterwards, PVDF membrane was blotted with primary 
antibody with appropriate dilution in 5% milk 0.1% TBST for overnight at 
4
°
C. On the next day, the membrane was washed with 0.1% TBST thrice, for 
10 minutes each time. This was followed by incubation of membrane in 
secondary antibody with appropriate dilution in 5% milk 0.1% TBST for 1 
hour at room temperature. The PVDF membrane was washed with 0.1% 
TBST thrice, for 10 minutes each time after secondary antibody incubation. 
Antibodies used were listed in Table 2.6 along with respective dilutions. 
Chemiluminescence was developed using SuperSignal West Pico 
Chemiluminescent Substrate or SuperSignal West Femto Maximum 
Sensitivity Substrate (Thermo Scientific). Chemiluminescence signal was 
detected by ChemiDoc MP System (Bio-Rad, Hercules, CA, USA) or Pierce 
CL-XPosure
TM
 Film (Thermo Scientific). Signal quantification was done 
using Image Lab software or Quantity One software with densitometer 
respectively. 
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Table 2.6 List of antibodies used in western blot with respective dilutions. 
Primary antibody 
Antibody 
dilution 
Secondary Antibody 
Antibody 
dilution 
SAMD9 rabbit polyclonal 
antibody (HPA021319 Sigma-
Aldrich, St. Louis, MO, USA) 
1:2500 
Polyclonal goat anti-rabbit 
immunoglobulins/HRP 
(P0448 Dako, Copenhagen, 
Denmark) 
1:1500 
PSMB9 rabbit polyclonal 
antibody (sc-28809 Santa Cruz, 
Dallas, Texas, USA) 
1:200 
Polyclonal goat anti-rabbit 
immunoglobulins/HRP 
(P0448 Dako) 
1:1500 
β-actin monoclonal mouse IgG 
antibody (Sigma-Aldrich) 
1:15000 
Sheep anti-mouse IgG HRP-
linked antibody (NA931V 
GE Healthcare, Little 
Chalfont, UK) 
1:20000 
 
2.10 Phenotypic Assays 
2.10.1 Proliferation Assay 
Proliferation assay was done through measurement of viable cells after gene 
silencing. At first, cells serum starvation was done 24 hours before seeding for 
transfection. Complete culture medium was replaced with serum-free medium. 
Afterwards, seeded cells growing on 6-well plate were silenced with specific 
siRNA. At 48 hours post transfection, cell viability was measured using MTS 
solution ([3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) (CellTiter 96® AQueous Non-Radioactive Cell 
Proliferation Assay) (Promega). Culture medium was removed from the 6-well 
plate. Complete medium with MTS was prepared by mixing complete medium 
and MTS solution at ratio of 5:1. 1.8ml of complete medium with MTS was 
added to 6-well plate with growing cells. Absorbance at 490nM was measured 
with spectrometer after incubation of the cells at 37C 5%CO2 for 1 to 4 hours. 
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2.10.2 Migration Assay 
Migration assay was performed using Transwell migration chamber (Corning, 
NY, USA). Migration chambers in the format of 24-well plate were hydrated 
with serum free medium. 200μl and 600μl of serum free medium were added 
into upper and lower compartment of chamber respectively and incubated for 
2 hours in 37C 5% CO2. Cells with gene silenced were harvested and cell 
count was done. Serum free medium in chamber was removed prior to cell 
seeding. 5×10^4 of cells in 200μl complete medium was seeded into upper 
compartment of chamber. Culture medium with 30% FBS was added into 
lower compartment of chamber to create chemoattractant gradient. Cells in 
chamber were allowed to grow and migrate for 24 hours with incubation in 
37C 5% CO2. 24 hours after cell seeding, chamber was washed with PBS and 
fix with 100% methanol for 15 minutes. This was followed by washing and 
staining by 0.5% crystal violet for 30 minutes. Chamber was washed to 
removed crystal violet and unwanted cells in inner surface. Pictures of cells 
were captured under microscope after air dry for calculation of migrated cell 
number. 
2.10.3 Invasion Assay 
Invasion assay was done using Transwell chamber (Corning). Coating of 
matrigel at bottom of chamber provide additional barrier to test invasiveness 
of cells. 100μl of Matrigel (300μg/ml) was added into each chamber at the 
beginning of experiment. This was followed by 2 hours incubation at 37C 
5%CO2. Cells with gene silenced were harvested and reseeded into the 
chamber at seeding density of 5×10^4 in 200μl complete medium. 600μl of 
culture medium with 30%FBS was added into lower compartment of the well 
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to form chemoattractant gradient. Cells were allowed to grow and invaded 
through matrigel for 24 hours at 37C 5%CO2. Subsequently, staining of 
chamber and calculation of invaded cells were done in similar manner as 
migration assay. 
2.10.4 Adhesion Assay 
Adhesion was done to test cell adherence to Collagen I (BD Biosciences, San 
Jose, CA, USA) and Fibronectin (BD Biosciences). 50μl of Collagen I 
(20μg/ml) and Fibronectin (20μg/ml) were added into each well of 9-well 
plate for coating. The 96-well plate was incubated in 4C for overnight. On the 
next day, Collagen I and Fibronectin were removed and washed with PBS. 
100μl of 1% BSA was added into same well for blocking by 1 hour incubation 
at room temperature. After 1 hour, BSA was removed and washed with PBS. 
2.5×10^4 of gene silenced cells were reseeded into each well. This was 
followed by 30 minutes incubation at 37C 5%CO2 for cells to adhere. 
Subsequently, non-adhered cells were washed off by PBS. Number of viable 
cells in each well was measured by MTS assay. 100μl of complete medium 
and 20μl of MTS solution were added into each well. Absorbance was 
measured at 490nM by spectrometer after incubation of 1 to 4 hours. 
2.11 DNA Microarray 
Global gene expression of silenced samples was measured through DNA 
microarray using Affymetrix Human U133 Plus 2.0 Array (Affymax, 
Cupertino, CA, USA). Total RNA was extracted from cell samples using RNA 
extraction kit. Quality check was done on total RNA before use for 
microarray. RNA concentration was determined by spectrophotometric 
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measurements (BioSpec-Mini, Shimadzu, Tokyo, Japan). Quality of RNA was 
measured and presented as RNA Integrity Number (RIN) (Agilent 
Bioanalyzer) (Agilent Technologies, Santa Clara, CA, USA) to check 
existence of degradation product. Good quality total RNA was subjected for 
target preparation to amplify product and produce biotin labelled amplified 
RNA (Affymetrix 3' IVT Express Target Amplification, Labelling and Control 
Kit) (Affymax). Amplified RNA was fragmented and hybridised to 
Affymetrix Human U133 Plus 2.0 Array according to manufacturer protocol 
(Affymetrix GeneChip Hybridization, Wash and Stain Kit) (Affymax). 
Hybridized array was scanned by Affymetrix 3000 7G scanner. Scanned array 
image was inspected for hybridization efficiency. This was followed by data 
quality check from Afffymetrix GeneChip Operating Software. Final result 
was generated as CEL file from Affymetrix GeneChip Command Console 
software. Additional data quality check was done by RMA normalization 
(Expression Console 1.3 software) (Affymax). Gene expression analysis was 
done by Transcriptome Analysis console to determine gene expression 
changes.   
2.12 Statistical Analysis 
In order to determine the significance of data, different statistical test has been 
applied using GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, 
USA). Student's unpaired t-test, two tailed with 95% confidence interval has 
been use to test if two samples have equal mean. If there were more than two 
samples, one way ANOVA (analysis of variance) was used to check if all 
samples are equal. Tukey post test (95% confidence interval) was used to 
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compare all sample pairs to determine presence of significance difference 
between sample pairs.  
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CHAPTER 3 
RESULTS 
 
3.1 Functional role of HS6ST3 in growth and progression of 
MCF7 
3.1.1 Silencing of HS6ST3 in MCF7 
Previously Iravani (2011) had silenced HS6ST3 in MCF7 and investigated its 
functional role in breast cancer progression. This set of experiments was 
mainly to verify the validity of the siRNA being used for subsequent DNA 
microarray analysis. HS6ST3 siRNA (40347) was used to silence HS6ST3 
gene in MCF7. RT-qPCR result showed silencing efficiency of 69.94% after 
transfection of HS6ST3 siRNA (Figure 3.1). 
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Figure 3.1 HS6ST3 gene expression after transfection of HS6ST3 siRNA in 
MCF7. MCF7 transfected with scrambled siRNA was used as control. Total 
RNA was extracted 72 hours post transfection and HS6ST3 transcript level 
was measured by RT-qPCR. Result was presented as percentage of HS6ST3 
expression level in silenced samples as compared to control samples. Data 
was shown as mean ± SE, n=3, ** p <0.01. 
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3.1.2 Analysis of cell proliferation after silencing of HS6ST3 in 
MCF7 
Proliferation rate of MCF7 was measured after transfection of HS6ST3 siRNA. 
Cells were serum starved prior to transfection, and they continued to grow for 
72 hours after transfection. Measurement of amount of live cells at that point 
showed that HS6ST3 silencing cause reduction of 60.47% in cell number 
comparing to normal growing MCF7 (Figure 3.2). 
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Figure 3.2 Analysis of cell proliferation after transfection of HS6ST3 in 
MCF7. MCF7 transfected with scrambled siRNA was used as control. Cells 
were serum starved prior to siRNA transfection. Presence of live cells was 
measured by MTS assay 72 hours post transfection. Measurement of 
absorbance at 490nm by spectrophotometer showed relative amount of live 
cells. Result was presented as percentage of live cells growing in silenced 
samples as compared to control samples. Data was shown as mean ± SE, n=3, 
* p <0.05, *** p <0.001. 
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3.1.3 Analysis of cell migration after silencing of HS6ST3 in 
MCF7 
Cell migration capability of MCF7 was evaluated by its ability to migrate 
through Transwell
®
 chamber. Cells were seeded into chamber at 72 hours post 
transfection of HS6ST3 siRNA. Chemoattractant gradient was created by 
increase FBS amount to 30% in lower compartment to induce cell migration. 
Microscopic view of chamber bottom surface showed significant decrease of 
migrated cells in silenced sample (Figure 3.3B) as compared to control (Figure 
3.3A). Cell number counts were done on five representative fields of chamber 
bottom surface for statistical analysis. Result showed reduction of 51.43% in 
cell migration after HS6ST3 silencing comparing to control (Figure 3.3C). 
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Figure 3.3 Analysis of cell migration in HS6ST3-silenced MCF7. MCF7 
transfected with scrambled siRNA was used as control. Transfected cells were 
seeded into Transwell
®
 chamber and allowed to migrate for 24 hours. Cells 
migration capability was quantified as number of cells migrated through 
chamber towards chemoattractant 30% FBS. Representative microscopic 
images of control (A) and silenced (B) after staining of chamber were 
displayed. Bar chart (C) showed result as percentage of migrated cells in 
silenced group as compared to control group. Data was shown as mean ± SE, 
n=3, *** p <0.001. 
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3.1.4 Analysis of cell invasion after silencing of HS6ST3 in 
MCF7 
Cell invasiveness of MCF7 was evaluated by its ability to invade and migrate 
through Transwell
®
 chamber coated with matrigel. Cells were seeded into 
chamber at 72 hours post transfection of HS6ST3 siRNA. Chemoattractant 
gradient was created by increase FBS amount to 30% in lower compartment to 
induce cell invasion. Microscopic view of chamber bottom surface showed 
significant decrease of invaded cells in silenced sample (Figure 3.4B) as 
compared to control (Figure 3.4A). Cell number counts were done on five 
representative fields of chamber bottom surface for statistical analysis. Result 
showed reduction of 42.74% in cell invasion after HS6ST3 silencing 
comparing to control (Figure 3.4C). 
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Figure 3.4 Analysis of cell invasion in HS6ST3-silenced MCF7. MCF7 
transfected with scrambled siRNA was used as control. Transfected cells were 
seeded into Transwell
®
 chamber coated with matrigel and allowed to invade 
and migrate for 24 hours. Cell invasiveness was quantified as number of cells 
that have invaded and migrated through chamber towards chemoattractant 
30% FBS. Representative microscopic images of control (A) and silenced (B) 
after staining of chamber were displayed. Bar chart (C) showed result as 
percentage of invaded cells in silenced group as compared to control group. 
Data was shown as mean ± SE, n=3, ** p <0.01. 
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3.2 Genome wide expression profiling in HS6ST3-silenced 
MCF7 
Genome wide expression profiling was done by DNA microarray analysis. 
Affymetrix Human U133 Plus 2.0 Array was used for analysis of HS6ST3-
silenced MCF7. Total RNA was extracted from HS6ST3-silenced and control 
MCF7 samples. The RNA samples were sent to Origene Company for 
processing. The company have taken several steps and measures to ensure 
good data quality being produced from DNA microarray analysis. Results 
were derived from the DNA microarray experiment report. 
3.2.1 RNA Quality Check 
Quality check was done by Origene Company through spectrophotometric 
measurements and RIN (RNA Integrity Number) determination to check 
presence and absence of RNA degradation products. Spectrophotometer 
measured concentration (ng/ul) and ratio 260/280 of total RNA; results were 
presented in Table 3.1.  Agilant Bioanalyzer analysis showed gel like image 
with distinct band of 28S subunit and 18S subunit in all samples (Figure 
3.5A), while spectrum analysis showed sharp peaks at 18S and 28S indicating 
highly intact RNA in all samples (Figure 3.5B). As a result, RIN of control 
samples was 10 and RIN of silenced samples were 9.87 (Table 3.1); RIN of 10 
represents good RNA integrity. 
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Figure 3.5 Agilant Bioanalyzer analysis of total RNA quality from HS6ST3-
selenced MCF7. Gel like image of each sample (A) showed presence of 28S 
subunit (upper band) and 18S subunit (lower band). Electropherogram of 
each sample (B) was used for detection of 18S and 28S peaks. Silenced 
samples were transfected with HS6ST3 siRNA, control samples were 
transfected with scrambled siRNA. 
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Table 3.1 RNA quality check and concentration measurement for used in DNA 
microarray analysis. RNA quality check included RIN (RNA Integrity Number) 
and 260/280 ratio. Silenced samples were transfected with HS6ST3 siRNA, 
control samples were transfected with scrambled siRNA. Data was shown as 
mean ± SE. 
Sample Control Silenced 
Concentration 
(ng/ul) 
458.33 ± 23.64 202.15 ± 4.99 
Ratio 260/280 2.20 ± 0.01 2.16 ± 0.02 
RIN 10.00 ± 0.00 9.87 ± 0.03 
 
3.2.2 Target Preparation aRNA (Amplified RNA) Quality 
Check 
RNA need to amplified and labelled with biotin before array hybridization. 
This target preparation step start with RNA being reverse transcribed to cDNA 
template. The cDNA template was used to produce biotin labelled aRNA. 
Quality check was done by spectrophotometric measurement showing yield 
(ug), concentration (ng/ul) and ratio 260/280. Measurements were presented in 
Table 3.2. aRNA was then fragmented and followed by hybridization to 
Affymetrix Human U133 Plus 2.0 Array. 
Table 3.2 Amplified RNA quality check and concentration measurement for 
subsequent array hybridization. Amplified RNA quality check included yield 
from target preparation and 260/280 ratio. Silenced samples were transfected 
with HS6ST3 siRNA, control samples were transfected with scrambled siRNA. 
Data was shown as mean ± SE. 
Sample Control Silenced 
Yield (ug) 67.17 ± 1.88 65.00 ± 3.78 
Concentration 
(ng/ul) 
1343.33 ± 37.57 1300.00 ± 75.50 
Ratio 260/280 2.07 ± 0.00 2.07 ± 0.00 
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3.2.3 Array Data Quality Check  
After array hybridization, arrays were scanned using Affymetrix 3000 7G 
scanner. Expression console 1.3 software was used for data quality check. 
RMA (Robust Multi-array Average) was performed on samples to generate 
quality control metrics as shown in Table 3.3. 
Table 3.3 Array data quality check of HS6ST3-silenced MCF7. Metrics that 
had been used included background, 3'/5' GAPDH, scaling factor, RawQ and 
% Present. Silenced samples were transfected with HS6ST3 siRNA, control 
samples were transfected with scrambled siRNA. Data was shown as mean ± 
SE. 
Sample Control Silenced 
Background 35.27 ± 0.09 36.85 ± 1.34 
3'/5' GAPDH 1.11 ± 0.02 1.11 ± 0.02 
Scaling Factor 4.55 ± 0.52 3.80 ± 0.44 
RawQ 1.09 ± 0.03 1.15 ± 0.05 
% Present 44.64 ± 0.68 46.32 ± 0.77 
 
3.2.4 Genome wide expression analysis from DNA microarray 
Gene expression changes were calculated based on intensity value from 
microarray data by Transcriptome Analysis Console. List of upregulated and 
downregulated genes was filtered out by criteria of absolute fold change >2 
and p-value <0.05. In total, there were 220 upregulated genes and 179 
downregulated genes. Table 6.1 in Appendix (Chapter 6) has listed genes that 
were differentially regulated in HS6ST3-silenced MCF7 as compared to 
control MCF7. Initially, genes were categorized according to their annotated 
Gene Ontology (GO) biological process by Protein Annotation through 
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Evolutionary Relationship (PANTHER) classification system (Mi et al., 
2013). Based on information from Gene Ontology, genes were manually 
examined and assigned into cancer relevant biological processes such as 
angiogenesis, apoptotic process, cell adhesion, cell migration, cell 
proliferation, immune response and regulation of gene expression. (Ashburner 
et al., 2000) Figure 3.6 showed the distribution of differentially regulated 
genes in each of the biological processes. After extensive literature review, 9 
genes were found to be playing important roles in breast cancer progression 
and agree with HS6ST3 silencing phenotype changes. They are CEACAM1, 
IFNB1, IRF7, NMI, PML, RARRES3, SP100, STAT1 and TNFSF10. RT-qPCR 
was performed to verify their mRNA upregulation in DNA microarray 
analysis. All of them showed comparable gene upregulation but differed in 
magnitude of fold change (Figure 3.7A). DNA gel electrophoresis of PCR 
amplified samples showed single PCR product with correct size (Figure 3.7B).    
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Figure 3.6 Biological process distributions of differentially regulated genes in 
HS6ST3-silenced MCF7. Unclassified genes were not plotted in the graph. 
There were 80 upregulated unclassified genes and 90 downregulated 
unclassified genes. 
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Figure 3.7 Verification gene expression changes in DNA microarray by RT-
qPCR. RT-qPCR and DNA microarray fold change values were compared in 
chart (A). Representative PCR product from each amplification was used for 
DNA gel electrophoresis (B) to verify product size. For RT-qPCR result, data 
was shown as mean ± SE, n=3. 
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3.3 Functional Role of SAMD9 in Growth and Progression of 
MCF7  
According to NCBI Reference Sequence Database (RefSeq), SAMD9 is a 
protein with sterile alpha motif domain localizing to cytoplasm (Pruitt et al., 
2014). It may have certain role in regulation of cell growth and apoptosis. 
Alternate splicing can produce different SAMD9 transcript variants but they 
have encoded the same SAMD9 protein (Pruitt et al., 2014). SAMD9 was 
observed to form helical polymer structure which was suggested can be used 
to form large protein complex or sterile alpha motif polymers (Knight et al., 
2011). SAMD9 expression is tightly regulated by interferon gamma (IFN-γ) 
(Hershkovitz et al., 2011). However the exact molecular function of SAMD9 
is unknown. 
 Mutation of SAMD9 was found to cause normophosphotemic familial 
tumoral calcinosis (NFTC). (Chefetz et al., 2008) NFTC will develop over 
area with repeated trauma and associated with marked inflammation. SAMD9 
has been suspected to be tumour suppressor gene because patients of acute 
myeloid leukemia, myelodysplastic symptom and juvenile myelomonocytic 
leukemia have frequent SAMD9 heterozygous deletion. (Asou et al., 2009) In 
addition, evidences suggested that SAMD9 could regulate tissue calcification, 
inflammation, cell migration and cell death. (Hershkovitz et al., 2011; Tanaka 
et al., 2010) Treating human glioblastoma U251MG with inactivated Sendai 
virus particle (HVJ-E) or IFN-β can induce SAMD9 expression and cause cell 
death (Tanaka et al., 2010). In the study, silencing of SAMD9 can reduce HVJ-
E and IFN- β cell induced cell death. In non small cell lung cancer, 
Results 
57 
 
knockdown of SAMD9 can increase proliferation, migration and invasion in 
H1299 cell line, while overexpression of SAMD9 can suppress proliferation 
and invasion in A549 cell line (Ma et al., 2014). Implantation of SAMD9 
shRNA-transfected H1299 in severe combined immunodeficiency mice has 
shown increase tumour formation (Ma et al., 2014). This suggested that 
SAMD9 could have similar role in HS6ST3 silenced breast cancer. SAMD9 
upregulation could mediate the phenotypes that were observed in silencing of 
HS6ST3 in human breast cancer. In addition, its inducibility by IFN-α and 
IFN-β can fit into finding from literature review that silencing of HS6ST3 
could have activated interferon signalling pathway. Therefore it was chosen as 
potential downstream target of HS6ST3 for further study. SAMD9 has not 
been studied in human breast cancer. Functional characterisation has to be 
done by gene silencing to have basic understanding about role of SAMD9 in 
breast cancer. 
3.3.1 Verification of SAMD9 upregulation after silencing of 
HS6ST3 in MCF7 
SAMD9 was one of potential downstream molecules of HS6ST3. In genome 
wide analysis of HS6ST3-silenced MCF7 by microarray, SAMD9 mRNA was 
upregulated for 18.12 fold (Table 3.4). RT-qPCR was performed to verify the 
expression changes in microarray data. Result showed that there was 13.67 
fold increases in mRNA level (Figure 3.8). Western blot was used to measure 
SAMD9 protein changes. It showed that there was 20.91 fold increases in 
SAMD9 protein after silencing of HS6ST3 in MCF7 (Figure 3.9). 
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Figure 3.8 SAMD9 mRNA expression level after silencing of HS6ST3 in 
MCF7. MCF7 transfected with scrambled siRNA was used as control. Total 
RNA of HS6ST3-silenced MCF7 was extracted 72 hours post transfection. 
SAMD9 transcript level was measured by RT-qPCR and shown as fold change 
relative to control. Data was shown as mean ± SE, n=3, *** p <0.001.  
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Figure 3.9 SAMD9 protein expression after silencing of HS6ST3 in MCF7. 
MCF7 transfected with scrambled siRNA was used as control. Total protein 
was extracted 72 hours post transfection. Western blot was used to detect 
presence of SAMD9 (184kDa) and β-actin (43kDa) as loading control (A). 
Quantitative analysis was done by Image Lab software. Result was presented 
as normalized fold change of SAMD9 protein level against β-actin in silenced 
sample as compared to control (B). Data was shown as mean ± SE, n=3, * p 
<0.05. (Note: This western blot was done on a same blot as Figure 3.18A. 
Stripping and re-blotting of same PVDF membrane was done. Therefore both 
figures shared the same β-actin control band image.) 
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3.3.2 Expression of SAMD9 across different human normal 
breast epithelial and cancer cell lines 
Expression level of SAMD9 was evaluated in panel of human normal breast 
epithelial cell lines (MCF10A and MCF12A) and breast cancer cell lines 
(T47D, MCF7 and ZR75-1). All of them showed significant difference in 
SAMD9 expression as compared to MCF10A. MCF12A exhibited 1.49 
increase of SAMD9 expression, while T47D, MCF7 and ZR75-1 showed 
74.47%, 96.39% and 89.31% decrease in SAMD9 expression respectively 
(Figure 3.10). This has formed the basis of hypothesis that SAMD9 has 
tumour suppressive effect as it was highly expressed in normal breast 
epithelial cells but suppressed in breast cancer cell lines. 
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Figure 3.10 SAMD9 mRNA expression level across different human normal 
breast epithelial and cancer cell lines. SAMD9 gene expression was measured 
by RT-qPCR and MCF10A was used as reference point. Data was shown as 
mean ± SE, n=3, * p <0.05, ** p <0.01, *** p <0.001.       
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3.3.3 SAMD9 expression level in SAMD9-silenced MCF7 
3.3.3.1 Evaluation of SAMD9 transcript level 
To investigate the role of SAMD9 in breast cancer, SAMD9 was knocked 
down by transfection of siRNA in MCF7 to check how it can affect cells 
cancer phenotypes. Two SAMD9 siRNA (S2 and S4) were used to silence 
SAMD9 gene in MCF7. RT-qPCR result showed decrease in 70.9% and 
66.95% in SAMD9 mRNA expression after transfection of S2 (Figure 3.11A) 
and S4 (Figure 3.11B) respectively.  
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Figure 3.11 SAMD9 mRNA expression after transfection of SAMD9 siRNA 
sequence 2 (siSAMD9 S2) and siRNA sequence 4 (siSAMD9 S4) in MCF7. 
MCF7 transfected with scrambled siRNA was used as control. Total RNA was 
extracted 48 hours post transfection and SAMD9 transcript level was 
measured by RT-qPCR. Result was presented as percentage of SAMD9 
expression level in siSAMD9 S2 (A) and siSAMD9 S4 (B) as compared to 
control. Data was shown as mean ± SE, n=3, ** p <0.01, *** p <0.001. 
 
3.3.3.2 Evaluation of SAMD9 protein level 
Protein expression of SAMD9 was evaluated after gene silencing in MCF7. 
Western blot analysis showed markedly decrease in protein expression in both 
S2 and S4 silenced samples (Figure 3.12A). Intensity of the protein bands 
were quantified by Image Lab software for statistical analysis. It showed 
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45.84%  and 74.99%  decrease in SAMD9 protein level after silencing by S2 
(Figure 3.12B) and S4 (Figure 3.12C) respectively. 
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Figure 3.12 SAMD9 protein expression after transfection of SAMD9 siRNA 
sequence 2 (siSAMD9 S2) and sequence 4 (siSAMD9 S4) in MCF7. MCF7 
transfected with scrambled siRNA was used as control. Total protein was 
extracted 72 hours post transfection. Western blot was used to detect presence 
of SAMD9 (184kDa) and β-actin (43kDa) as loading control (A). Quantitative 
analysis was done by Image Lab software. Result was presented as percentage 
of normalized SAMD9 protein level against β-actin in S2 (B) and S4 (C) as 
compared to control. Data was shown as mean ± SE, n=3, * p <0.05, ** p 
<0.01. 
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3.3.4 Phenotypic assays of MCF7 after silencing of SAMD9 
3.3.4.1 Analysis of cell proliferation after silencing of SAMD9 in MCF7 
Proliferation rate of MCF7 was measured after transfection of SAMD9 siRNA. 
Cells were serum starved prior to transfection, and they continued to grow for 
72 hours after transfection. Measurement of amount of live cells at that point 
showed that silencing by S2 and S4 cause reduction of 8.97% and 16.06% in 
cell number respectively comparing to normal growing MCF7 (Figure 3.13). 
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Figure 3.13 Analysis of cell proliferation after transfection of SAMD9 siRNA 
sequence 2 (siSAMD9 S2) and sequence 4 (siSAMD9 S4) in MCF7. MCF7 
transfected with scrambled siRNA was used as control. Cells were serum 
starved prior to siRNA transfection. Presence of live cells was measured by 
MTS assay 72 hours post transfection. Measurement of absorbance at 490nm 
by spectrophotometer showed relative amount of live cells. Result was 
presented as percentage of live cells growing in S2 and S4 as compared to 
control. Data was shown as mean ± SE, n=3, * p <0.05, ** p <0.01. 
 
Results 
64 
 
3.3.4.2 Analysis of cell migration after silencing of SAMD9 in MCF7 
Cell migration capability of MCF7 was evaluated by its ability to migrate 
through Transwell
®
 chamber. Cells were seeded into chamber at 48 hours post 
transfection of SAMD9 siRNA. Chemoattractant gradient was created by 
increasing FBS amount to 30% in the lower compartment to induce cell 
migration. Microscopic view of chamber bottom surface showed significant 
decrease of migrated cells in both S2 (Figure 3.14B) and S4 (Figure 3.14C) as 
compared to control (Figure 3.14A). Cell number counts were done on five 
representative fields of chamber bottom surface for statistical analysis. Result 
showed reduction of 32.11% and 36.97% in cell migration after SAMD9 
silencing by S2 and S4 respectively as compared to control (Figure 3.13D). 
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Figure 3.14 Analysis of cell migration in SAMD9-silenced MCF7. MCF7 
transfected with scrambled siRNA was used as control. Transfected cells were 
seeded into Transwell
®
 chamber and allowed to migrate for 24 hours. Cells 
migration capability was quantified as number of cells migrated through 
chamber towards chemoattractant 30% FBS. Representative microscopic 
images of control (A), siSAMD9 S2 (B) and siSAMD9 S4 (C) after staining of 
chamber were displayed. Bar chart (D) showed result as percentage of 
migrated cells in S2 and S4 as compared to control. Data was shown as mean 
± SE, n=3, ** p <0.01. 
 
 
(A) (B) (C) 
(D) 
Results 
66 
 
3.3.4.3 Analysis of cell invasion after silencing of SAMD9 in MCF7 
Cell invasiveness of MCF7 was evaluated by its ability to invade and migrate 
through Transwell
®
 chamber coated with matrigel. Cells were seeded into 
chamber at 48 hours post transfection of SAMD9 siRNA. Chemoattractant 
gradient was created by increasing FBS amount to 30% in the lower 
compartment to induce cell invasion. Microscopic view of chamber bottom 
surface showed significant decrease of invaded cells in both S2 (Figure 3.15B) 
and S4 (Figure 3.15C) as compared to control (Figure 3.15A). Cell number 
counts were done on five representative fields of chamber bottom surface for 
statistical analysis. Result showed reduction of 38.1% and 36.32% in cell 
invasion after SAMD9 silencing by S2 and S4 respectively comparing to 
control (Figure 3.15D). 
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Figure 3.15 Analysis of cell invasion in SAMD9-silenced MCF7. MCF7 
transfected with scrambled siRNA was used as control. Transfected cells were 
seeded into Transwell
®
 chamber coated with matrigel and allowed to invade 
and migrate for 24 hours. Cell invasiveness was quantified as number of cells 
that have invaded and migrated through chamber towards chemoattractant 
30% FBS. Representative microscopic images of control (A), siSAMD9 S2 (B) 
and siSAMD9 S4 (C) after staining of chamber were displayed. Bar chart (D) 
showed result as percentage of invaded cells in S2 and S4 as compared to 
control. Data was shown as mean ± SE, n=3, *** p <0.001. 
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3.3.4.4 Analysis of cell adhesion after silencing of SAMD9 in MCF7 
MCF7 cell adhesion against fibronectin and collagen I were evaluated after 
silencing of SAMD9. Cells were reseeded into 96-well plate coated with either 
fibronectin or collagen I at 48 hours post transfection. After 30 minutes of cell 
adherence time, non-attached cells were washed off and amount of remaining 
live cells was measured by MTS assay. In first set of data (Figure 3.16A and 
Figure 3.16B), S2 and S4 SAMD9-silenced MCF7 showed different properties 
in adhesion assay. It was found that only S4 SAMD9-silenced MCF7 showed 
significant decrease of 22.67% in cell adhesion against collagen I as compared 
to control. (Figure 3.16B).  In second repeat of the adhesion assay (Figure 
3.16C), result showed significant difference between S2 and S4 SAMD9 
silenced MCF7 but not significant when they were compared to control. In 
third repeat of adhesion assay (Figure 3.16D), there was no significant change 
in adhesion capacity being observed in every group. Although 3 sets of 
adhesion assays were done under the same condition, no consistent results 
were obtained and it was unable to reach a conclusion. 
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Figure 3.16 Analysis of cell adhesion in SAMD9-silenced MCF7. MCF7 
transfected with scrambled siRNA was used as control. Transfected cells were 
seeded into 96-well plate coated with Fibronectin or Collagen I. Cells were 
allowed to adhere for 30 minutes and being washed off afterwards. Cell 
adhesion was quantified as percentage of cells remained after washing step. 
MTS assay was used to measure number of live cells. Measurement of 
absorbance at 490nm by spectrophotometer showed relative amount of live 
cell. Result was presented as percentage of adhered cells in S2 and S4 as 
compared to control. (A) and (B) are first set of adhesion assay. (C) and (D) 
are data acquired from second and third repeats of adhesion assay 
respectively. 3 sets of experiments have been done under same condition. Data 
was shown as mean ± SE, n=6, ** p <0.01, ***p<0.001. 
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3.4 Functional Role of PSMB9 in Growth and Progression of 
MCF7  
Phenotypic assays results of SAMD9 silencing did not agree with hypothesis 
that SAMD9 has tumour suppressive function as potential downstream 
molecule of HS6ST3. Therefore another potential downstream molecule was 
selected for study. 
 PSMB9 is a beta-type catalytic subunit of immunoproteosome. 
According to RefSeq, PSMB9 gene is located at major histocompatibility 
complex (MHC) class II region (Pruitt et al., 2014). Its expression could be 
induced by IFN-γ to replace catalytic subunit 1 in immunoproteosome. 
Immunoproteosome is responsible for processing of class I MHC peptides in 
ATP/ubiquitin-dependent process in non-lysosomal pathway. PSMB9 gene 
product needs to undergo proteolytic processing to generate mature subunit 
(Pruitt et al., 2014). 
 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 
(TAP1), TAP2, PSMB8 and PSMB9 were found to involve in processing and 
transport of class I MHC antigen to endoplasmic reticulum (Wright et al., 
1995). TAP can mediate transport of peptides produced by 
immunoproteosome into endoplasmic reticulum to bind to MHC (Seliger et 
al., 2002). The process is crucial for tumour antigen presentation to cytotoxic 
T-lymphocytes. Colon adenocarcinoma, basophilic leukemia, small cell lung 
carcinoma and hepatocellular carcinoma that were deficient in presentation of 
tumour antigen, also lack in TAP1 and PSMB9 expression but not TAP2 and 
PSMB8 (Singal et al., 1996). Knock down PSMB9 expression by antisense 
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mRNA can cease the tumour antigen presentation to cytotoxic T-lymphocytes 
(Sibille et al., 1995). However, PSMB9 and p53 deficient mice only showed 
non-significant increase in tumour incidence (Johnsen et al., 2001). This 
indicated that tumourigenesis might not be effectively prevented by native 
immune system (Johnsen et al., 2001).  
 Nevertheless, PSMB9 deficient mice have high risk in developing 
uterine leiomyosarcomas (LMS) (Hayashi et al., 2006). Human uterine LMS 
was found to have absence of PSMB9 expression but not human uterine 
leiomyoma (LMA) (Hayashi et al., 2010). G871E mutation in Janus Kinase 1 
(JAK1) was detected in SKN human uterine LMS cell line, preventing PSMB9 
expression to avoid anti-tumour specific immunity (Hayashi et al., 2006). 
Positive expression of PSMB9 and negative expression of cyclin B1 has 
potential to be used as diagnostic biomarker for human LMS (Hayashi et al., 
2014). 
 In DNA microarray gene list, TAP1, TAP2, PSMB8 and PSMB9 were 
upregulated after silencing of HS6ST3. In addition, major histocompatibility 
complex, class I, A (HLA-A), HLA-B, HLA-C, HLA-E, HLA- F and HLA-G 
were also upregulated at the same time. This suggested silencing of HS6ST3 
could activate antigen presentation pathway. Literature review showed 
evidences that the tumour antigen presentation pathway have important role in 
tumour progression. Activation of the pathway might be responsible for 
phenotypes that were observed in HS6ST3-silenced breast cancer. In 
particular, PSMB9 is an important player of the pathway which has not been 
studied in breast cancer. It could be a potential downstream target of HS6ST3. 
Therefore it is of interest to do in-depth study about PSMB9 in breast cancer. 
Results 
73 
 
Functional characterization of PSMB9 -in breast cancer was carried out. This 
was done by gene silencing of PSMB9 and subsequent phenotypic assays. 
3.4.1 Verification of PSMB9 upregulation after silencing of 
HS6ST3 in MCF7 
PSMB9 was another of potential downstream molecule of HS6ST3. In 
genome wide analysis of HS6ST3-silenced MCF7 by microarray, PSMB9 
mRNA was upregulated for 10.56 fold (Table 3.4). RT-qPCR was performed 
to verify the expression changes in microarray data. Result showed that there 
was 8.43 fold increases in mRNA level (Figure 3.17). Western blot was used 
to measure PSMB9 protein changes. It showed that there was 1.92 fold 
increases in PSMB9 protein after silencing of HS6ST3 in MCF7 (Figure 3.18). 
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Figure 3.17 PSMB9 mRNA expression level after silencing of HS6ST3 in 
MCF7. MCF7 transfected with scrambled siRNA was used as control. Total 
RNA of HS6ST3-silenced MCF7 was extracted 72 hours post transfection. 
PSMB9 transcript level was measured by RT-qPCR and shown as fold change 
relative to control. Data was shown as mean ± SE, n=3, ** p <0.01. 
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Figure 3.18 PSMB9 protein expression after silencing of HS6ST3 in MCF7. 
MCF7 transfected with scrambled siRNA was used as control. Total protein 
was extracted 72 hours post transfection. Western blot was used to detect 
presence of PSMB9 (23kDa) and β-actin (43kDa) as loading control (A). 
Quantitative analysis was done by Image Lab software. Result was presented 
as normalized fold change of PSMB9 protein level against β-actin in silenced 
sample as compared to control (B). Data was shown as mean ± SE, n=3, *** 
p <0.001. (Note: This western blot was done on a same blot as Figure 3.9A. 
Stripping and re-blotting of same PVDF membrane was done. Therefore both 
figures shared the same β-actin control band image.) 
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3.4.2 PSMB9 expression level in PSMB9-silenced MCF7 
3.4.2.1 Evaluation of PSMB9 transcript level 
To investigate the role of PSMB9 in breast cancer, PSMB9 was knocked down 
by transfection of siRNA in MCF7 to check how it can affect cells cancer 
phenotypes. Two PSMB9 siRNA (S1 and S2) were used to silence PSMB9 
gene in MCF7. RT-qPCR result showed decrease in 91.91% and 85.77% in 
PSMB9 expression after transfection of S1 and S2 respectively (Figure 3.19). 
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Figure 3.19 PSMB9 mRNA expression after transfection of PSMB9 siRNA 
sequence 1 (siPSMB9 S1) and siRNA sequence 2 (siPSMB9 S4) in MCF7. 
MCF7 transfected with scrambled siRNA was used as control. Total RNA was 
extracted 48 hours post transfection and PSMB9 transcript level was 
measured by RT-qPCR. Result was presented as percentage of PSMB9 
expression level in siPSMB9 S1 and siPSMB9 S2 as compared to control. 
Data was shown as mean ± SE, n=3, *** p <0.001. 
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3.4.2.2 Evaluation of PSMB9 protein level 
Protein expression of PSMB9 was evaluated after gene silencing in MCF7. 
Western blot analysis showed no significant changes in protein expression in 
both S1 and S2 silenced samples (Figure 3.20A). Intensity of the protein bands 
were quantified by densitometer and Quantity One software for statistical 
analysis. A previous study has found that PSMB9 activity could be affected 
silencing of PSMB9 without significant change in PSMB9 precursor band 
intensity (Niewerth, 2014). It showed that immunoproteosome activity can be 
inhibited by PSMB9 silencing (Niewerth, 2014). Therefore phenotypic assays 
were carried out in PSMB9-silenced MCF7 even though the protein level and 
activity of PSMB9 has not been demonstrated yet. 
 
 
 
 
Results 
77 
 
 
Control siPSMB9 S1
0.0
0.5
1.0
1.5
N
o
rm
a
li
ze
d
 F
o
ld
 C
h
a
n
g
e
Control siPSMB9 S2
0.0
0.5
1.0
1.5
2.0
N
o
rm
a
li
ze
d
 F
o
ld
 C
h
a
n
g
e
 
Figure 3.20 PSMB9 protein expression after transfection of PSMB9 siRNA 
sequence 1 (siPSMB9 S1) and sequence 2 (siPSMB9 S4) in MCF7. MCF7 
transfected with scrambled siRNA was used as control. Total protein was 
extracted 72 hours post transfection. Western blot was used to detect presence 
of PSMB9 (23kDa) and β-actin (43kDa) as loading control (A). Quantitative 
analysis was done by Image Lab software. Result was presented as normalized 
fold change of PSMB9 protein level against β-actin in S1 (B) and S2 (C) as 
compared to control. Data was shown as mean ± SE, n=3. 
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3.4.3 Phenotypic Assays of MCF7 after Silencing of PSMB9 
3.4.3.1 Analysis of cell proliferation after silencing of PSMB9 in MCF7 
Proliferation rate of MCF7 was measured after transfection of PSMB9 siRNA. 
Cells were serum starved prior to transfection, and they continued to grow for 
72 hours after transfection. Measurement of amount of live cells at that point 
showed that silencing by S1 and S2 cause no significant difference in cell 
number comparing to normal growing MCF7 (Figure 3.21). 
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Figure 3.21 Analysis of cell proliferation after transfection of PSMB9 siRNA 
sequence 1 (siPSMB9 S1) and sequence 2 (siPSMB9 S2) in MCF7. MCF7 
transfected with scrambled siRNA was used as control. Cells were serum 
starved prior to siRNA transfection. Presence of live cells was measured by 
MTS assay 72 hours post transfection. Measurement of absorbance at 490nm 
by spectrophotometer showed relative amount of live cells. Result was 
presented as percentage of live cells growing in S1 and S2 as compared to 
control. Data was shown as mean ± SE, n=3.  
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3.4.3.2 Analysis of cell migration after silencing of PSMB9 in MCF7 
Cell migration capability of MCF7 was evaluated by its ability to migrate 
through Transwell
®
 chamber. Cells were seeded into chamber at 48 hours post 
transfection of PSMB9 siRNA. Chemoattractant gradient was created by 
increasing FBS amount to 30% in the lower compartment to induce cell 
migration. Microscopic view of chamber bottom surface showed significant 
decrease of migrated cells in both S1 (Figure 3.22B) and S2 (Figure 3.22C) as 
compared to control (Figure 3.22A). Cell number counts were done on five 
representative fields of chamber bottom surface for statistical analysis. Result 
showed reduction of 32.98% and 31.93% in cell migration after PSMB9 
silencing by S1 and S2 respectively as compared to control (Figure 3.22D). 
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Figure 3.22 Analysis of cell migration in PSMB9-silenced MCF7. MCF7 
transfected with scrambled siRNA was used as control. Transfected cells were 
seeded into Transwell
®
 chamber and allowed to migrate for 24 hours. Cells 
migration capability was quantified as number of cells migrated through 
chamber towards chemoattractant 30% FBS. Representative microscopic 
images of control (A), siPSMB9 S1 (B) and siPSMB9 S2 (C) after staining of 
chamber were displayed. Bar chart (D) showed result as percentage of 
migrated cells in S1 and S2 as compared to control. Data was shown as mean 
± SE, n=3, *** p <0.001. 
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3.4.3.3 Analysis of cell invasion after silencing of PSMB9 in MCF7 
Cell invasiveness of MCF7 was evaluated by its ability to invade and migrate 
through Transwell
®
 chamber coated with matrigel. Cells were seeded into 
chamber at 48 hours post transfection of PSMB9 siRNA. Chemoattractant 
gradient was created by increasing FBS amount to 30% in the lower 
compartment to induce cell invasion. Microscopic view of chamber bottom 
surface showed significant decrease of invaded cells in both S1 (Figure 3.23B) 
and S2 (Figure 3.23C) as compared to control (Figure 3.23A). Cell number 
counts were done on five representative fields of chamber bottom surface for 
statistical analysis. Result showed reduction of 33.95% and 34.38% in cell 
invasion after PSMB9 silencing by S1 and S2 respectively as compared to 
control (Figure 3.23D). 
 
 
 
 
 
 
Results 
82 
 
 
C
on
tr
ol
si
PS
M
B
9 
S1
si
PS
M
B
9 
S2
0
50
100
*** ***
R
e
la
ti
v
e
 I
n
v
a
d
e
d
 C
e
ll
 N
u
m
b
e
r 
(%
)
 
Figure 3.23 Analysis of cell invasion in PSMB9-silenced MCF7. MCF7 
transfected with scrambled siRNA was used as control. Transfected cells were 
seeded into Transwell
®
 chamber coated with matrigel and allowed to invade 
and migrate for 24 hours. Cell invasiveness was quantified as number of cells 
that have invaded and migrated through chamber towards chemoattractant 
30% FBS. Representative microscopic images of control (A), siPSMB9 S1 (B) 
and siPSMB9 S2 (C) after staining of chamber were displayed. Bar chart (D) 
showed result as percentage of invaded cells in S1 and S2 as compared to 
control. Data was shown as mean ± SE, n=3, *** p <0.001. 
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3.4.3.4 Analysis of cell adhesion after silencing of PSMB9 in MCF7 
MCF7 cell adhesion against fibronectin and collagen I were evaluated after 
silencing of PSMB9. Cells were reseeded into 96-well plate coated with either 
fibronectin or collagen I at 48 hours post transfection. After 30 minutes of cell 
adherence time, non-attached cells were washed off and amount of remaining 
live cells was measured by MTS assay.  In fibronectin, S1 and S2 PSMB9-
silenced MCF7 showed amount of adhered cells increase for 68.93% and 
72.17% respectively as compared control (Figure 3.24). In Collagen I, S1 and 
S2 PSMB9-silenced MCF7 showed decrease amount of adhered cells for 
18.25% and 29.02% respectively as compared to control (Figure 3.24).   
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Figure 3.24 Analysis of cell adhesion in PSMB9-silenced MCF7. MCF7 
transfected with scrambled siRNA was used as control. Transfected cells were 
seeded into 96-well plate coated with Fibronectin or Collagen I. Cells were 
allowed to adhere for 30 minutes and being washed off afterwards. Cell 
adhesion was quantified as percentage of cells remained after washing step. 
MTS assay was used to measure number of live cells. Measurement of 
absorbance at 490nm by spectrophotometer showed relative amount of live 
cell Result was presented as percentage of adhered cells in S1 and S2 as 
compared to control.. Data was shown as mean ± SE, n=6, * p <0.05, ** p 
<0.01. 
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CHAPTER 4 
DISCUSSION 
The aim of this study is to investigate HS6ST3 downstream signalling 
pathway and identify novel downstream target that was responsible for 
phenotypic changes after silencing of HS6ST3. Functional characterisation of 
HS6ST3 suggested that it is an oncogene because silencing of HS6ST3 can 
cause decrease in cell proliferation, cell migration and cell invasion (Iravani, 
2011). Furthermore, HS6ST3 can promote cell adhesion against fibronectin 
and collagen I (Iravani, 2011). However the exact mechanism of these 
phenotypic changes was unknown. It could be mediated by alteration of HS 
structure and function through HS6ST3's capability to modify HS 6-O 
sulfation status. On the other hand, HS6ST3 could interact with other partners 
to carry out unconventional function. In order to study it, it is important to 
known the genome wide expression changes following silencing of HS6ST3.  
4.1 Genome wide expression profiling in HS6ST3-silenced 
MCF7 
DNA microarray was used to generate overview of gene expression changes 
after silencing of HS6ST3 in breast cancer cells. To ensure the quality of DNA 
microarray data, series of quality checks were done in multiple steps. After 
applying filter of fold change larger than 2 and p-value smaller than 0.05, 
there are in total 220 upregulated genes and 159 downregulated genes. This 
suggested that HS6ST3 is a prominent gene regulator. After extensive 
literature review, 2 potential HS6ST3 downstream target genes have been 
selected for further study, SAMD9 and PSMB9. They have never been studied 
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in breast cancer. Nevertheless, several studies suggested that both of them 
could play certain role in other cancer progression. SAMD9 and PSMB9 were 
upregulated after silencing of HS6ST3. Hypothesis is that both SAMD9 and 
PSMB9 could have tumour suppressor functions that were inhibited in the 
presence of HS6ST3 expression in the context of breast cancer. To test the 
hypothesis, functional characterisation in breast cancer was carried out 
through silencing of SAMD9 and PSMB9 separately. 
4.2 Functional Characterization of SAMD9 and PSMB9 in 
Human Breast Cancer 
Functional characterisation include several cancer phenotypic assays such as 
cell proliferation assay, cell migration assay, cell invasion assay and cell 
adhesion assay. Cell proliferation assay can measure amount of live cells in 
particular sample. Comparison of treatment sample to control sample can 
indicate changes in cell growth rate. Cell migration and invasion are metastatic 
characteristics of malignant cancer cells. Malignant cancer cells need to break 
through extracellular matrix to invade adjacent tissue and get into blood 
stream or lymph vessel. During the process, malignant cells would migrate 
from original tumour site and colonize in new site. Cell migration and 
invasion assay mimic this metastasis process. Cells movement across 
Transwell
®
 chamber was measure in migration assay. In the meanwhile, cells 
need to break through matrigel which has similar component as extracellular 
matrix in invasion assay to cross the Transwell
®
 chamber. Cell adhesion also 
related to cancer metastasis. Metastatic cells generally have lower adhesion 
capability in order to facilitate cell movement. 
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4.2.1 Functional Role of SAMD9 in Growth and Progression of MCF7  
As a potential downstream molecule of HS6ST3, SAMD9 was upregulated 
after silencing of HS6ST3. It could contribute to HS6ST3-silenced mediated 
tumour suppressive phenotypes. Assessing SAMD9 mRNA expression level 
across human breast normal epithelial and cancer cell lines also showed it has 
relatively high expression in normal breast epithelial cell lines MCF10A and 
MCF12A but low expression level in breast cancer cell lines T47D, MCF7 and 
ZR75-1. Thus hypothesis was that SAMD9 could exert tumour suppression 
effect in human breast cancer. Functional characterisation was carried out to 
assess the hypothesis. 
 In SAMD9, silencing can cause several phenotypic changes. First of 
all, reduce expression of SAMD9 resulted in slower growth rate. Besides that, 
it can also decrease cell migration and invasion. However the SAMD9-silenced 
adhesion assays data was inconclusive. Introduction of siRNA into MCF7 
might induce variation in cell adhesion to fibronectin and collagen I. SAMD9 
S2 silenced MCF7 showed relatively consistent result, no significant change in 
cell adhesion. But SAMD9 S4 silenced MCF7 showed greater variation in cell 
adhesion. The result could vary from lower to higher cell adhesion capacity 
when compared to control. This might due to S4 was more effective in 
knocking down SAMD9 protein level. Cell adhesion in MCF7 might become 
susceptible to variation when SAMD9 protein expression was sufficiently low. 
As such, variation in silencing efficiency among experiment might contribute 
to inconsistent result.  In future, different concentration of SAMD9 siRNA 
could be used for transfection in cell adhesion assay. This might help to 
determine whether MCF7 cell adhesion behave differently in the presence of 
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different SAMD9 protein levels. Besides that, overexpression of SAMD9 in 
breast cancer could be done to assess its effect on cell adhesion as well as 
other phenotypes. Nevertheless, role of SAMD9 in cell proliferation, 
migration and invasion suggested that SAMD9 could aid in breast cancer 
progression. The result contradict with the hypothesis of SAMD9 being 
tumour suppressor gene in breast cancer. Although SAMD9 expression was 
affected HS6ST3, it might not contribute to phenotypic changes in silencing of 
HS6ST3.  
 From literature review, there was no much evidence that support the 
data.  However, Tang et al. (2014) have found that overexpression of SAMD9 
has been correlated with metastasis of esophageal squamous cell carcinoma. 
On the other hand, silencing of SAMD9 in human fibroblast can increase Early 
Growth Response 1 (EGR1) expression (Hershkovitz et al., 2011). EGR1, a 
cancer suppressor gene, is nuclear protein transcriptional regulator that 
induces target genes for mitogenesis and differentiation (Pruitt et al., 2014). It 
has been found that breast, lung and brain cancer generally have low 
expression of EGR1 (Adamson & Mercola, 2002). EGR1 was required to 
induce apoptosis in response to stimuli and its restoration in cancer cells can 
suppress growth (Adamson & Mercola, 2002). In vivo rat mammary tumours 
have shown that Egr1 have tumour suppressive effect by deregulating cancer 
growth during tumourigenesis process (Huang et al., 1997). Furthermore, 
EGR1 can stimulate BRCA1 expression in HeLa cells (Shin et al., 2013). 
These evidences suggested that SAMD9 could have oncogenic effect by 
suppressing tumour suppressor gene EGR1. More study will be required to 
verify the possible alternate route. 
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4.2.2 Functional Role of PSMB9 in Growth and Progression of MCF7  
PSMB9 was upregulated in response to HS6ST3 silencing. Hence it was 
hypothesised to be tumour suppressor gene in breast cancer. However 
silencing of PSMB9 can cause decrease in cell migration and invasion. There 
was no significant change in cell proliferation. Besides, silencing of PSMB9 
resulted in inconclusive outcome; there was increase in adhesion against 
fibronectin but decrease in adhesion against collagen I. This indicated that 
PSMB9 has oncogenic properties contributing to metastasis. This contradicts 
with the proposed hypothesis. PSMB9 is unlikely to be downstream target 
gene of HS6ST3 that contribute to HS6ST3 silencing phenotypic changes. 
One issue about the PSMB9 silencing was that western blot could not detect 
any difference in protein level. This might due to relative stable expression of 
PSMB9 protein as compared to mRNA level as shown in RNA--mediated 
knock down of PSMB9 (Atkinson et al., 2012). Another reason could be that 
antibody that was used in western blot was unable to recognize mature form of 
PSMB9. Niewerth et al. (2014) has been able to silence PSMB9 by showing a 
fainter band as mature PSMB9 with molecular size smaller than precursor 
PSMB9. Although PSMB9 precursor protein (23kD) did not show significant 
difference, the study has been able to demonstrate decrease of 
immunoproteosome activity by silencing PSMB9 (Niewerth et al. 2014). 
Hence measurement immunoproteosome activity could be applied in future 
studies to verify PSMB9 activity. 
 There were some findings that could explain the observed breast 
cancer behaviour after PSMB9 silencing. In prostate cancer, it was found that 
PSMB9 have potential growth regulating role because PSMB9-rich PC-3 
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prostate cancer cell line was susceptible to growth inhibition by PSMB9-
specific inhibitor (Ho et al., 2007). Another study has also able to induce 
apoptosis of PC-3 by treatment of PSMB9 selective inhibitor, UK-101 
(Wehenkel et al., 2012).  In addition, PC-3 implanted nude mice receiving 
UK-101 treatment has resulted in significant (50-60%) tumour growth 
inhibition (Wehenkel et al., 2012). Downregulation of immunoproteosome can 
increase pro-apoptotic proteins such as Bax and cleaved caspase 3, caspase 9 
and poly (ADP-ribose) polymerase (PARP) (Cui et al., 2014). Besides that, 
human embryonic stem cells have showed downregulation of 
immunoproteosome as they were differentiating (Atkinson et al., 2012). 
Inhibition of both PSMB8 and PSMB9 can cause decrease of pluripotency 
cells while increase in differentiation marker (Atkinson et al., 2012). 
Knockdown of PSMB9 can also prevent skeletal muscle C2C12 cells to 
differentiate (Cui et al., 2014). These suggested that PSMB9 could play certain 
role in maintenance of cancer stem cell characteristic while suppressing 
differentiation.  In clear cell renal cell carcinoma, PSMB9 expression was 
associated with higher relative risk, poorer prognosis and decrease in overall 
survival in cancer patients (Peri et al., 2013).  In a most recent study, PSMB9 
and proteasome activator PA700 expression in breast cancer with absence of 
estrogen α-receptor was associated with tumour growth and progression of 
lymph node metastasis (Shashova et al., 2014). These evidences indicated that 
other than PSMB9-immunoproteosome tumour suppressing properties through 
tumour antigen processing and presentation, PSMB9 could promote tumour 
progression through unknown pathway. 
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4.3 Breast Cancer Related Genes in HS6ST3-silenced MCF7 
DNA Microarray Data  
 Screening through the list of differentially regulated genes in 
microarray, there are several well-established breast cancer related genes that 
agree with the action of HS6ST3. They are CEACAM1, IFNB1, IRF7, NMI, 
PML, RARRES3, SP100, STAT1 and TNFSF10. Their upregulation in DNA 
microarray data were verified by RT-qPCR. 
 Interferons are cytokines that exhibit antiproliferative activity and 
trigger immune response upon expression (Fish & Platanias, 2014). Interferon-
β (IFN- β) was encoded by IFNB1 gene, which showed increase expression 
after silencing of HS6ST3 in DNA microarray analysis. Treatment of IFN-β in 
breast cancer can suppress proliferation and angiogenesis while inducing 
apoptosis (Ambjørn et al., 2013). IFN-β was found to inhibit cell cycle 
progression and sensitize tumour to cytotoxicity of chemotherapy such as 
cisplatin, 5-fluorouracil and paclitaxel (Brickelmaier et al., 2002). It has also 
been used as combined therapy with retinoid acid and tamoxifen in metastatic 
breast cancer after chemotherapy (Recchia et al., 1998). The combined therapy 
was effective with minimal toxicity. Mesenchymal stem cell (MSC) has 
potential to be used as vehicle to target tumour and deliver intended gene 
product (Basel et al., 2014). Overexpressing IFN-β by MSC therapy can 
inhibit breast cancer proliferation and metastasis to lung and liver (Ling et al., 
2010). 
 STAT1 is another gene that was upregulated after HS6ST3 silencing. 
STAT is a transcription factor that is phosphorylated by receptor kinase in 
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response to cytokines and growth factors (Pruitt et al., 2014). It can form 
homo or heterodimer to translocate into nucleus to activate target gene 
transcription (Pruitt et al., 2014). STAT1 was frequently lost during breast 
cancer progression (Chan et al., 2012) .In breast cancer sensitized by retinoid 
acid, IFN-β can inhibit cell proliferation through activation of STAT1 (Kolla 
et al., 1996). In addition, in vitro study using MCF7 showed that STAT1 was 
crucial for growth suppression by MSC IFN-β (Ryu et al., 2014). All-trans 
retinoic acid (ATRA) treatment in MCF7 and MDA-MB-231 can also induce 
apoptosis through induction of retinoic acid receptor β expression and 
activation of STAT1 (Shang et al., 1999). Besides that, Stat1 deficient mice 
have higher risk in developing mammary tumour (Chan et al., 2012).  In 
contrast, Stat1 can inhibit mouse mammary gland tumour formation and 
HER2 mediated cellular transformation (Raven et al., 2011). These evidences 
suggested that STAT1 play a key role in regulation of breast cancer 
proliferation and apoptosis. 
 RARRES3 expression can be induced by retinoic acid and lead to 
decrease in proliferation (DiSepio et al., 1998). It was found to be a tumor 
suppressor gene. Silencing of HS6ST3 can induce expression of RARRES3. In 
breast cancer, transient overexpression of RARRES3 in T47D can inhibit 
colony expansion (DiSepio et al., 1998). Besides that, RARRES3 is negatively 
regulated by estrogen receptor activation. MCF7 and ZR-75-1 that were 
treated with 17beta-estradiol can suppress RARRES3 expression (Shyu et al., 
2005). In HER2 positive breast cancer patients with co-amplification of 
retinoic acid receptor alpha (RARα), ATRA and lapatinib combination therapy 
has resulted in synergetic effect (Paroni et al., 2012).  The study found that 
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ATRA can activate TGF-β signalling and induce RARRES3 expression which 
leads to stabilization of HER2 inhibition by lapatinib (Paroni et al., 2012). 
RARRES3 can also induce apoptosis through activation of capase-2 and 
caspase-3 and inhibit RAS/ mitogen-activated protein kinase pathway in 
ovarian cancer (Tsai et al., 2007). Furthermore, RARRES3 was found play 
certain role in cancer metastasis. Breast cancer patients with reduced 
expression of RARRES3 in primary tumour have higher risk of lung 
metastases (Morales et al., 2014). It showed that RARRES3 downregulation 
can facilitate adhesion of tumour cells to lung parenchyma which is crucial for 
metastasis initiation. In breast cancer, p53 function in cell proliferation and 
Wnt/ β-catenin signalling was found to be deregulated by induction of 
RARRES3 (Hsu et al., 2014). Wnt/ β-catenin signalling is key regulator for 
different biological process such as embryonic development, cell proliferation, 
cell fate decision and tumourigenesis. RARRES3 can target and modulate 
acylation status of Wnt and its co-receptor which can suppress epithelial-
mesenchymal transition and cancer stem cell properties (Hsu et al., 2014).  
 IRF7 is another gene which expression was induced by IFN-β and 
silencing of HS6ST3. This inducible expression is mainly observed in 
lymphoid tissue (Pruitt et al., 2014). In immortal fibroblast from p53 mutated 
Li-Fraumeni patients, IRF7 was found to be silenced by methylation at its 
promoter CpG island (Li et al., 2008). Restoration of IRF7 in those cells can 
suppress proliferation and induce cellular senescence (Li et al., 2008). In 
addition, activation of Irf7 in breast cancer mouse model with spontaneous 
bone metastasis can decrease incidence of bone metastasis and prolong 
survival (Bidwell et al., 2012) . The study showed that this action depended on 
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interferon signalling to trigger host immune system (Bidwell et al., 2012). 
IRF7 also involved in BRCA1 breast cancer suppression mechanism. BRCA1 
has important role in regulating transcription, DNA damage repair and cell 
cycle (Pruitt et al., 2014). Inherited BRCA1 lost of function mutation can 
increase female risk of breast cancer and ovarian cancer. BRCA1 can be 
activated by IFN-γ to induce transcription of STAT1, STAT2, IFN-α and IFN-
β (Buckley et al., 2007). IRF7 was activated as downstream target which 
induce apoptosis and trigger expression of IFN-β as positive feedback 
mechanism (Buckley et al., 2007). 
 BRCA1 can  associate with NMI to form tricomplex with c-Myc (Li et 
al., 2002). Besides that, NMI is an adaptor molecule that can interact with c-
Myc, n-Myc and STATs except STAT2 (Pruitt et al., 2014). Microarray data 
showed that silencing of HS6ST3 can upregulate NMI expression. Formation 
of the BRCA1-NMI-c-Myc complex can inhibit c-Myc ability to activate 
human telomerase reverse transcriptase gene (hTERT) which was important 
for carcinogenesis (Li et al., 2002).  In aggressive breast cancer cell lines, 
NMI was observed to have lower expression but it was inducible by IFN-γ 
(Fillmore et al., 2009). In vivo study showed that constitutive expression of 
NMI can suppress tumour growth, anchorage independent growth and 
invasion (Fillmore et al., 2009). Tumour growth suppression by NMI was 
mediated by inhibition of Wnt/β-catenin signalling pathway and subsequent c-
Myc activation through upregulation of DKK1 (Fillmore et al., 2009).  
 CEACAM1 is a glycoprotein belongs to immunoglobulin superfamily. 
CEACAM1 expression is regulated by IRF1 through interferon stimulated 
response element on CEACAM1 promoter (Gencheva et al., 2010). Primarily 
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it was found to mediate cell - cell adhesion and cellular signalling but later 
studies have shown that CEACAM1 have tumour suppressor function as well. 
CEACAM1 has been found to be deregulated in lung, prostate, colorectal and 
breast cancer (Beauchemin & Arabzadeh, 2013). CEACAM1 was observed to 
possess growth suppression function on breast cancer (Luo et al., 1997). Loss 
of CEACAM1 expression coincided with development of malignant phenotype 
in breast cancer (Riethdorf et al., 1997). In breast cancer, patients with low 
CEACAM1 expression level and high tumour grade have poorer prognosis 
than patients with high CEACAM1 expression level and low tumour grade 
(Wang et al., 2011). Treatment of breast cancer with Mullerian inhibiting 
substance (MLS) and IFN-γ can stimulate IRF1 and CEACAM1 expression. 
Subsequent activation of NFκB pathway would lead to growth suppression 
and induction of apoptosis (Tsuboi et al., 2003). At the same time, IRF-1 can 
regulate alternative splicing of CEACAM1 to produce short and long form 
products. In particular, restored expression of CEACAM1-(4S), short 
cytoplasmic isoform in MCF7 can help to revert it back to normal 
morphogenic phenotype along with lumen formation (Kirshner et al., 2003). 
Apoptosis during lumen formation is mediated by CEACAM1 through 
calpain-9 (CAPN9) and protein kinase C-delta (PRKCD) (Chen et al., 2010). 
Besides, CEACAM1 phosphorylation sites on cytoplasmic domain are crucial 
for its function. Single nucleotide mutation at Tyr488 or Ser503 could abolish 
tumour cell growth inhibition by CEACAM1 (Izzi et al., 1999; Estrera et al., 
2001). In microarray data, silencing of HS6ST3 can upregulate CEACAM1 
expression. Hence CEACAM1 might contribute to subsequent observed 
phenotypes, growth suppression and induction of apoptosis. 
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 PML was one of upregulated gene in HS6ST3-silenced MCF7. It is a 
transcription factor that act as tumour suppressor and responsible to regulate 
cell cycle and p53 response on oncogenic signal (Pruitt et al., 2014). Acute 
promyelocytic leukemia was caused by translocation of PML to replace RARα 
transactivation domain and form PML/RARα fusion protein (Goddard et al., 
1992). In other cancer, PML can interact with other protein like SP100 to form 
nuclear bodies that suppress growth and induce cellular senescence and 
apoptosis (Shimad et al., 2008). It has been well studied in breast cancer. 
Immunohistochemistry analysis of lymph node metastasis breast cancer has 
shown complete loss of PML expression (Gurrieri et al., 2004). Besides that, 
delivering of PML into MCF7 by adenovirus can inhibit cell proliferation, 
clonogenicity and tumourigenicity through cell cycle arrest at G1 phase (Le et 
al., 1998). Conversely, suppression of PML can inhibit irradiation-induced 
apoptosis of MCF7 through reduction of p53 activation (Bao-Lei et al., 2006). 
 PML interacting partner SP100 is of interest as well. They can form 
nuclear bodies through interaction mediated by small ubiquitin-like modifier 1 
(SUMO1) (Pruitt et al., 2014). SP100 can bind heterochromatin to function in 
gene regulation, immunity and tumourigenesis (Pruitt et al., 2014). Expression 
of SP100 can be induced by IFN-α, IFN-β and IFN-γ (Guldner et al., 1992; 
Grötzinger et al., 1996). It was identified as one of immunogenic antigen 
being detected from breast cancer patients' serum (Hansen et al., 2001). SP100 
was found to interact with v-ets avian erythroblastosis virus E26 oncogene 
homolog 1 (ETS1). It can block ETS1 transcriptional activation of matrix 
metallopeptidase 1 (MMP1) and urokinase plasminogen activator (uPA) that 
play important role in MDA-MB-231 invasion (Yordy et al., 2004). 
Discussion 
97 
 
 TNFSF10 is a cytokine of Tumour Necrosis Factor ligand family 
(Pruitt et al., 2014). Its expression can be activated by p53 to induce apoptosis 
and tumour suppression (Kuribayashi et al., 2008). Nonetheless breast cancer 
was commonly resistant to TNFSF10-induced cell death due to expression of 
NFκB (Keane et al., 2000; Rahman et al., 2009). Tamoxifen inactivation of 
estrogen receptor can help to sensitize breast cancer to TNFSF10-induced 
apoptosis (Lagadec et al., 2008). Besides, x-linked inhibitor of apoptosis 
(XIAP) inhibition also can sensitize breast cancer response to TNFSF10 
(Allensworth et al., 2012). In HS6ST3 silenced MCF7, XIAP-associated factor 
1 (XAF1), an inhibitor of XIAP, was upregulated. At the same time, 
upregulation of TNFSF10 could potentially induce apoptosis and suppress cell 
growth in MCF7.  
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CHAPTER 5 
CONCLUSION AND FUTURE STUDIES  
DNA microarray analysis has provided a general overview of what might be 
happening in a cell after silencing of HS6ST3. Silencing of HS6ST3 can induce 
expression of 220 genes while inhibiting expression 159 genes. This showed 
that HS6ST3 has potential to act as key regulator to cell function. 
 Careful scrutinization of the list of genes with extensive literature 
review suggested several possible signalling pathways that could be 
responsible for observed phenotypic changes. Interferon signalling pathway 
and TRAIL apoptotic pathway were among them. CEACAM1, IFNB1, IRF7, 
NMI, PML, RARRES3, SP100 and STAT1 that were verified to be upregulated 
have participated in interferon signalling pathway. TNFSF10 itself is the main 
player of TRAIL apoptotic pathway that induce apoptosis.  
  Two interferon inducible genes SAMD9 and PSMB9 were potential 
novel player in breast cancer. Functional characterization results did not 
support hypothesis that both of them have tumour suppressor functions in 
breast cancer. More experiments would be required to determine their roles in 
breast cancer progression. For example, experiments could be conducted in 
low serum condition as tumor suppressive effect could be revealed under 
different condition. Besides that, normal breast cell lines could be used for 
conducting similar gene silencing experiments to determine their roles. 
Overexpression studies can be done in future to corroborate current 
information. 
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 Although both SAMD9 and PSMB9 expression were induced upon 
HS6ST3 silencing, data suggested that they might actually counteract the 
phenotypic changes in MCF7. Double silencing of HS6ST3 with either 
SAMD9 or PSMB9 in MCF7 will be required to establish the extent of this 
counteraction. In addition, survey of PSMB9 expression levels in different 
breast cancer cell lines could be done to determine other suitable cell line for 
further examination. 
 Nevertheless, understanding of mechanism of HS6ST3 oncogenic 
properties will require further in-depth study. Overexpression studies of 
HS6ST3 could be done in breast cancer cells and normal breast epithelial cells 
to corroborate current findings. Elucidating of underlying signalling pathways 
will be important to expand our knowledge in breast cancer progression. This 
is crucial for identifying novel diagnostic or prognostic biomarker and 
therapeutic target for breast cancer. Personalized treatment for breast cancer 
will be a trend in near future, a clearer and more detailed big picture of breast 
cancer tumourigenesis would be of great value. 
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CHAPTER 6 
APPENDIX 
Table 6.1 Genome wide gene expression changes after silencing of HS6ST3 in 
MCF7. Genes were categorized according to their annotated gene ontology 
biological process. Within each category, genes sorted from highest to lowest 
fold change. Positive fold change value represented upregulated gene 
expression; negative fold change value represented downregulated gene 
expression. Filtering criteria included fold change >2 or <-2 and p-value 
<0.05. 
Biological 
Process 
RefSeq 
Transcript ID 
Gene Symbol Gene Title 
Fold 
Change 
P-value 
Angiogenesis 
(8 genes) 
NM_001565 CXCL10 
chemokine (C-X-C motif) 
ligand 10 
11.58 0.0039 
NM_004184  
NM_173701  
NM_213645  
NM_213646 
WARS 
tryptophanyl-tRNA 
synthetase 
2.26 0.0074 
 NM_006775  
NM_206853  
NM_206854  
NM_206855 
QKI 
QKI, KH domain containing, 
RNA binding 
2.25 0.0147 
 NM_001172895  
NM_001172896  
NM_001172897  
NM_001753 
CAV1 
caveolin 1, caveolae protein, 
22kDa 
-4.94 0.0047 
 NM_001124 ADM adrenomedullin -2.97 0.0070 
 
NM_017902 HIF1AN 
hypoxia inducible factor 1, 
alpha subunit inhibitor 
-2.89 0.0122 
 
NM_015278 SASH1 
SAM and SH3 domain 
containing 1 
-2.67 0.0139 
 NM_001134445  
NM_012137 
DDAH1 
dimethylarginine 
dimethylaminohydrolase 1 
-2.18 0.0069 
Apoptotic 
Process 
(42 genes) 
NM_017523  
NM_199139  
NR_046396 
NR_046397 
NR_046398 
XAF1 XIAP associated factor 1 110.97 0.0166 
NM_001547 IFIT2 
interferon-induced protein 
with tetratricopeptide repeats 
2 
90.76 0.0130 
 NM_002038  
NM_022872  
IFI6 
interferon, alpha-inducible 
protein 6 
42.15 0.0158 
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NM_022873 
 
NM_032206 NLRC5 
NLR family, CARD domain 
containing 5 
13.09 0.0028 
 
NM_022168 IFIH1 
interferon induced with 
helicase C domain 1 
12.81 0.0022 
 
NM_007315  
NM_139266 
STAT1 
signal transducer and 
activator of transcription 1, 
91kDa 
11.64 0.0040 
 NM_002176 IFNB1 interferon, beta 1, fibroblast 9.09 0.0040 
 
NM_004159  
NM_148919 
PSMB8 
proteasome (prosome, 
macropain) subunit, beta 
type, 8 (large multifunctional 
peptidase 7) 
8.29 0.0022 
 NM_001190942  
NM_001190943  
NM_003810  
NR_033994 
TNFSF10 
tumor necrosis factor 
(ligand) superfamily, 
member 10 
5.65 0.0075 
 NM_000585  
NM_172174  
NM_172175  
NR_037840 
IL15 interleukin 15 4.81 0.0050 
 NM_004223  
NM_198183 
UBE2L6 
ubiquitin-conjugating 
enzyme E2L 6 
4.40 0.0040 
 NM_080745  
NM_182985 
TRIM69 tripartite motif containing 69 4.35 0.0045 
 NM_002198 IRF1 interferon regulatory factor 1 4.07 0.0021 
 
NM_032855 HSH2D 
hematopoietic SH2 domain 
containing 
3.48 0.0063 
 
NM_002801 PSMB10 
proteasome (prosome, 
macropain) subunit, beta 
type, 10 
2.96 0.0037 
 
NM_005419  
NM_198332 
STAT2 
signal transducer and 
activator of transcription 2, 
113kDa 
2.84 0.0052 
 
NM_006290 TNFAIP3 
tumor necrosis factor, alpha-
induced protein 3 
2.82 0.0162 
 
NM_003405 YWHAH 
tyrosine 3-
monooxygenase/tryptophan 
5-monooxygenase activation 
protein, eta polypeptide 
2.67 0.0022 
 NM_001025107  
NM_001111  
NM_001193495  
NM_015840  
NM_015841 
ADAR 
adenosine deaminase, RNA-
specific 
2.39 0.0045 
 NM_001008211  
NM_001008212  
NM_001008213  
NM_021980 
OPTN optineurin 2.38 0.0097 
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NM_001144925  
NM_001178046  
NM_002462 
MX1 
myxovirus (influenza virus) 
resistance 1, interferon-
inducible protein p78 
(mouse) 
2.30 0.0193 
 NM_001172566  
NM_001172567  
NM_001172568  
NM_001172569  
NM_002468 
MYD88 
myeloid differentiation 
primary response gene (88) 
2.17 0.0037 
 NM_001195053  
NM_001195054  
NM_001195055  
NM_001195056  
NM_001195057  
NM_004083 
DDIT3 
DNA-damage-inducible 
transcript 3 
2.14 0.0053 
 NM_016618 KRCC1 lysine-rich coiled-coil 1 2.11 0.0223 
 NM_001142315  
NM_001142316  
NM_005574 
LMO2 
LIM domain only 2 
(rhombotin-like 1) 
2.07 0.0212 
 
NM_003806 HRK 
harakiri, BCL2 interacting 
protein (contains only BH3 
domain) 
2.06 0.0474 
 
NM_002818 PSME2 
proteasome (prosome, 
macropain) activator subunit 
2 (PA28 beta) 
2.02 0.0146 
 NM_001008540  
NM_003467 
CXCR4 
chemokine (C-X-C motif) 
receptor 4 
2.02 0.0359 
 
NM_025165 ELL3 
elongation factor RNA 
polymerase II-like 3 
2.00 0.0312 
 NM_001048200  
NM_005734 
HIPK3 
homeodomain interacting 
protein kinase 3 
2.00 0.0031 
 NM_144590 ANKRD22 ankyrin repeat domain 22 -5.16 0.0177 
 NM_001080430  
NM_001146188 
TOX3 
TOX high mobility group 
box family member 3 
-3.89 0.0024 
 NM_001127321  
NM_001127322  
NM_012117 
CBX5 chromobox homolog 5 -3.50 0.0113 
 
NM_001034061  
NM_018941 
CLN8 
ceroid-lipofuscinosis, 
neuronal 8 (epilepsy, 
progressive with mental 
retardation) 
-3.14 0.0193 
 NM_001267048  
NM_001267049  
NM_020775  
NR_049773  
NR_049774 
KIAA1324 KIAA1324 -2.64 0.0031 
 NM_001098620  
NM_001128911  
NM_001128912  
NM_001128913  
PCBP2 poly(rC) binding protein 2 -2.53 0.0122 
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NM_001128914  
NM_005016  
NM_031989 
 NM_001141919  
NM_001141920  
NM_175569 
XG Xg blood group -2.42 0.0455 
 NM_004041  
NM_020251 
ARRB1 arrestin, beta 1 -2.32 0.0070 
 
NM_153690 FAM43A 
family with sequence 
similarity 43, member A 
-2.25 0.0096 
 NM_000611  
NM_001127223  
NM_001127225  
NM_001127226  
NM_001127227  
NM_203329  
NM_203330  
NM_203331 
CD59 
CD59 molecule, complement 
regulatory protein 
-2.09 0.0321 
 NM_014292 CBX6 chromobox homolog 6 -2.09 0.0168 
 NM_004226 STK17B serine/threonine kinase 17b -2.01 0.0074 
Cell 
Adhesion 
(15 genes) 
NM_005567 LGALS3BP 
lectin, galactoside-binding, 
soluble, 3 binding protein 
5.87 0.0050 
NM_001710 CFB complement factor B 5.54 0.0228 
 NM_001256252  
NM_001256253  
NM_001256254  
NM_001256255  
NM_001974 
EMR1 
egf-like module containing, 
mucin-like, hormone 
receptor-like 1 
4.06 0.0149 
 NM_001025079  
NM_001025080  
NM_001777  
NM_198793 
CD47 CD47 molecule 2.28 0.0119 
 
NM_024036 LRFN4 
leucine rich repeat and 
fibronectin type III domain 
containing 4 
2.01 0.0274 
 
NM_144593 RHEBL1 
Ras homolog enriched in 
brain like 1 
2.00 0.0171 
 NM_007000 UPK1A uroplakin 1A -3.68 0.0061 
 NM_001167667  
NM_004934 
CDH18 cadherin 18, type 2 -3.03 0.0089 
 NM_000393 COL5A2 collagen, type V, alpha 2 -2.65 0.0024 
 NM_005723 TSPAN5 tetraspanin 5 -2.32 0.0194 
 
NM_014400 LYPD3 
LY6/PLAUR domain 
containing 3 
-2.19 0.0195 
 
NM_002208 ITGAE 
integrin, alpha E (antigen 
CD103, human mucosal 
lymphocyte antigen 1; alpha 
polypeptide) 
-2.08 0.0040 
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 NM_001207063  
NM_001207064  
NM_001207065  
NM_001207066  
NM_001338 
CXADR 
coxsackie virus and 
adenovirus receptor 
-2.05 0.0145 
 
NM_023940 RASL11B 
RAS-like, family 11, 
member B 
-2.02 0.0272 
 
NM_207361 FREM2 
FRAS1 related extracellular 
matrix protein 2 
-2.01 0.0351 
Cell 
Migration 
(16 genes) 
NM_003641  
NM_006435 
IFITM1 
IFITM2 
interferon induced 
transmembrane protein 1 
interferon induced 
transmembrane protein 2 
29.78 0.0118 
NM_001146102  
NM_001146103  
NM_001146104  
NM_001146105  
NM_001146106  
NM_031458 
PARP9 
poly (ADP-ribose) 
polymerase family, member 
9 
9.15 0.0039 
 NM_001080391  
NM_001206701  
NM_001206702  
NM_001206703  
NM_001206704  
NM_003113 
SP100 SP100 nuclear antigen 5.95 0.0191 
 
NM_004335 BST2 
bone marrow stromal cell 
antigen 2 
4.94 0.0037 
 NM_001012333  
NM_001012334  
NM_002391 
MDK 
midkine (neurite growth-
promoting factor 2) 
2.87 0.0049 
 
NM_005980 S100P 
S100 calcium binding 
protein P 
2.86 0.0040 
 NM_001024912  
NM_001184813  
NM_001184815  
NM_001184816  
NM_001205344  
NM_001712 
CEACAM1 
carcinoembryonic antigen-
related cell adhesion 
molecule 1 (biliary 
glycoprotein) 
2.53 0.0378 
 
NM_001080435 WHAMM 
WAS protein homolog 
associated with actin, golgi 
membranes and microtubules 
2.11 0.0345 
 NM_004390  
NM_148979 
CTSH cathepsin H 2.08 0.0264 
 NM_001085049  
NM_001252090  
NM_001252091  
NM_001252092  
NM_001252093  
NM_012219 
MRAS 
muscle RAS oncogene 
homolog 
2.04 0.0210 
 NM_001008540  CXCR4 chemokine (C-X-C motif) 2.02 0.0359 
Appendix 
105 
 
NM_003467 receptor 4 
 NM_001003407  
NM_001003408  
NM_002313  
NM_006720 
ABLIM1 actin binding LIM protein 1 -2.84 0.0052 
 NM_018222 PARVA parvin, alpha -2.25 0.0134 
 NM_001195610  
NM_016356 
DCDC2 
doublecortin domain 
containing 2 
-2.13 0.0293 
 NM_130847 AMOTL1 angiomotin like 1 -2.07 0.0332 
 NM_000259  
NM_001142495 
MYO5A 
myosin VA (heavy chain 12, 
myoxin) 
-2.05 0.0179 
Cell 
Proliferation 
(44 genes) 
NM_001031683  
NM_001549 
IFIT3 
interferon-induced protein 
with tetratricopeptide repeats 
3 
213.48 0.0394 
NM_002985 CCL5 
chemokine (C-C motif) 
ligand 5 
50.75 0.0074 
 
NM_014398 LAMP3 
lysosomal-associated 
membrane protein 3 
35.24 0.0054 
 
NM_005409 CXCL11 
chemokine (C-X-C motif) 
ligand 11 
17.18 0.0022 
 
NM_004585 RARRES3 
retinoic acid receptor 
responder (tazarotene 
induced) 3 
16.45 0.0052 
 
NM_002800  
NM_148954 
PSMB9 
proteasome (prosome, 
macropain) subunit, beta 
type, 9 (large multifunctional 
peptidase 2) 
10.56 0.0040 
 
NM_002178 IGFBP6 
insulin-like growth factor 
binding protein 6 
8.21 0.0012 
 
NM_002201 ISG20 
interferon stimulated 
exonuclease gene 20kDa 
7.81 0.0022 
 
NM_002514 NOV 
nephroblastoma 
overexpressed 
5.52 0.0111 
 
NM_172140 IL29 
interleukin 29 (interferon, 
lambda 1) 
5.34 0.0106 
 NM_032579 RETNLB resistin like beta 4.90 0.0136 
 NM_003141 TRIM21 tripartite motif containing 21 4.74 0.0265 
 NM_001135651  
NM_001135652  
NM_002759 
EIF2AK2 
eukaryotic translation 
initiation factor 2-alpha 
kinase 2 
4.61 0.0025 
 NM_001015051  
NM_001024630  
NM_004348 
RUNX2 
runt-related transcription 
factor 2 
3.82 0.0085 
 
NM_033109 PNPT1 
polyribonucleotide 
nucleotidyltransferase 1 
3.56 0.0022 
 NM_001085486  
NM_001093726  
SEPP1 selenoprotein P, plasma, 1 2.66 0.0262 
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NM_005410 
 NM_005953 MT2A metallothionein 2A 2.60 0.0077 
 NM_005115  
NM_017458 
MVP major vault protein 2.47 0.0332 
 NM_002675  
NM_033238  
NM_033239  
NM_033240  
NM_033244  
NM_033246  
NM_033247  
NM_033249  
NM_033250 
PML promyelocytic leukemia 2.27 0.0410 
 NM_005952 MT1X metallothionein 1X 2.22 0.0096 
 NM_003714 STC2 stanniocalcin 2 2.16 0.0118 
 NM_002820  
NM_198964  
NM_198965  
NM_198966 
PTHLH 
parathyroid hormone-like 
hormone 
2.15 0.0322 
 
NM_002467 MYC 
v-myc myelocytomatosis 
viral oncogene homolog 
(avian) 
2.14 0.0057 
 NM_005951 MT1H metallothionein 1H 2.12 0.0024 
 NM_032551 KISS1R KISS1 receptor 2.10 0.0155 
 NM_031479 INHBE inhibin, beta E 2.10 0.0497 
 NM_005950 MT1G metallothionein 1G 2.01 0.0395 
 
NM_003221 TFAP2B 
transcription factor AP-2 
beta (activating enhancer 
binding protein 2 beta) 
-3.57 0.0057 
 NM_001243080  
NM_001243081  
NM_001422  
NM_198381 
ELF5 
E74-like factor 5 (ets domain 
transcription factor) 
-3.20 0.0126 
 NM_000055 BCHE butyrylcholinesterase -3.15 0.0353 
 NM_001004128  
NM_002826 
QSOX1 
quiescin Q6 sulfhydryl 
oxidase 1 
-2.83 0.0131 
 NM_001178091  
NM_001178092  
NM_001178093  
NM_001178094  
NM_005504 
BCAT1 
branched chain amino-acid 
transaminase 1, cytosolic 
-2.73 0.0118 
 
NM_004586 RPS6KA3 
ribosomal protein S6 kinase, 
90kDa, polypeptide 3 
-2.68 0.0025 
 NM_018304 PRR11 proline rich 11 -2.39 0.0022 
 
NM_016653  
NM_133646 
ZAK 
sterile alpha motif and 
leucine zipper containing 
kinase AZK 
-2.34 0.0104 
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 NM_001145306  
NM_001259 
CDK6 cyclin-dependent kinase 6 -2.33 0.0138 
 NM_001206836  
NM_004663 
RAB11A 
RAB11A, member RAS 
oncogene family 
-2.30 0.0134 
 
NM_003144 SSR1 
signal sequence receptor, 
alpha 
-2.21 0.0150 
 NM_001064  
NM_001135055  
NM_001135056  
NM_001258028  
NR_047579  
NR_047580 
TKT transketolase -2.16 0.0128 
 NM_001206615  
NM_001206616  
NM_012153 
EHF ets homologous factor -2.15 0.0192 
 NM_018063 HELLS helicase, lymphoid-specific -2.14 0.0150 
 NM_001130447  
NM_018097 
HAUS2 
HAUS augmin-like complex, 
subunit 2 
-2.04 0.0185 
 NM_001079670  
NM_030925 
CAB39L 
calcium binding protein 39-
like 
-2.02 0.0390 
 
NM_001244949  
NM_020918 
GPAM 
glycerol-3-phosphate 
acyltransferase, 
mitochondrial 
-2.00 0.0286 
Immune 
Response 
(53 genes) 
NM_001548 IFIT1 
interferon-induced protein 
with tetratricopeptide repeats 
1 
201.39 0.0449 
NM_006820 IFI44L 
interferon-induced protein 
44-like 
159.42 0.0209 
 NM_006417 IFI44 interferon-induced protein 44 112.60 0.0097 
 NM_001032731  
NM_002535  
NM_016817 
OAS2 
2'-5'-oligoadenylate 
synthetase 2, 69/71kDa 
88.21 0.0111 
 NM_001261825  
NM_003733  
NM_198213 
OASL 
2'-5'-oligoadenylate 
synthetase-like 
65.37 0.0089 
 
NM_017631 DDX60 
DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 60 
44.33 0.0069 
 NM_001032409  
NM_002534  
NM_016816 
OAS1 
2'-5'-oligoadenylate 
synthetase 1, 40/46kDa 
35.44 0.0056 
 
NM_005101 ISG15 
ISG15 ubiquitin-like 
modifier 
32.65 0.0128 
 NM_021105 PLSCR1 phospholipid scramblase 1 14.81 0.0057 
 
NM_016323 HERC5 
HECT and RLD domain 
containing E3 ubiquitin 
protein ligase 5 
12.89 0.0022 
 NM_002053 GBP1 guanylate binding protein 1, 12.57 0.0045 
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interferon-inducible 
 
NM_014314 DDX58 
DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 58 
12.04 0.0040 
 
NM_002463 MX2 
myxovirus (influenza virus) 
resistance 2 (mouse) 
11.86 0.0431 
 
NM_006187 OAS3 
2'-5'-oligoadenylate 
synthetase 3, 100kDa 
10.83 0.0039 
 
NM_138456 BATF2 
basic leucine zipper 
transcription factor, ATF-
like 2 
9.58 0.0109 
 
NM_001012967 DDX60L 
DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 60-like 
7.44 0.0022 
 
NM_015474 SAMHD1 
SAM domain and HD 
domain 1 
6.99 0.0042 
 
NM_005514 HLA-B 
major histocompatibility 
complex, class I, B 
6.21 0.0050 
 NM_020119  
NM_024625 
ZC3HAV1 
zinc finger CCCH-type, 
antiviral 1 
6.13 0.0043 
 NM_014788  
NM_033219  
NM_033220  
NM_033221 
TRIM14 tripartite motif containing 14 5.95 0.0021 
 
NM_012420 IFIT5 
interferon-induced protein 
with tetratricopeptide repeats 
5 
5.82 0.0040 
 NM_014349  
NM_030644  
NM_145639  
NM_145640  
NM_145641  
NM_145642  
NR_027833  
NR_027834  
NR_027835 
APOL3 apolipoprotein L, 3 5.35 0.0119 
 
NM_000544  
NM_018833 
TAP2 
transporter 2, ATP-binding 
cassette, sub-family B 
(MDR/TAP) 
5.16 0.0060 
 
NM_172138  
NM_172139 
IL28A 
IL28B 
interleukin 28A (interferon, 
lambda 2) 
interleukin 28B (interferon, 
lambda 3) 
4.93 0.0061 
 NM_021034  
NR_049759 
IFITM3 
interferon induced 
transmembrane protein 3 
4.80 0.0063 
 NM_001098478  
NM_001098479  
NM_018950 
HLA-F 
major histocompatibility 
complex, class I, F 
4.47 0.0028 
 
NM_000593 TAP1 
transporter 1, ATP-binding 
cassette, sub-family B 
(MDR/TAP) 
4.35 0.0022 
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 NM_018284 GBP3 guanylate binding protein 3 4.28 0.0124 
 
NM_003335 UBA7 
ubiquitin-like modifier 
activating enzyme 7 
3.99 0.0118 
 
NM_006435 IFITM2 
interferon induced 
transmembrane protein 2 
3.97 0.0037 
 NM_001242524  
NM_001242525  
NM_033554 
HLA-DPA1 
major histocompatibility 
complex, class II, DP alpha 1 
3.94 0.0096 
 NM_001243042  
NM_002117  
XM_003403557  
XM_003403558  
XM_003403559  
XM_003403560  
XM_003403561  
XM_003403562  
XM_003403563  
XM_003403564  
XM_003403565  
XM_003403566  
XM_003403567  
XM_003403568  
XM_003403569   
HLA-C 
major histocompatibility 
complex, class I, C 
3.86 0.0029 
 
NM_019111 HLA-DRA 
major histocompatibility 
complex, class II, DR alpha 
3.61 0.0074 
 
NM_015660 GIMAP2 
GTPase, IMAP family 
member 2 
3.53 0.0111 
 NM_001242758  
NM_002116 
HLA-A 
major histocompatibility 
complex, class I, A 
3.03 0.0050 
 NM_001197246  
NM_001197247  
NM_001197248  
NM_001197249  
NM_001242803  
NM_006994  
NM_007047  
NM_197974 
BTN3A2 
BTN3A3 
butyrophilin, subfamily 3, 
member A2 
butyrophilin, subfamily 3, 
member A3 
2.91 0.0271 
 
NM_002127 HLA-G 
major histocompatibility 
complex, class I, G 
2.90 0.0010 
 NM_004048 B2M beta-2-microglobulin 2.79 0.0036 
 NM_001130140  
NM_022350 
ERAP2 
endoplasmic reticulum 
aminopeptidase 2 
2.69 0.0054 
 NM_001267706  
NM_014143  
NR_052005 
CD274 CD274 molecule 2.60 0.0063 
 NM_001033503  
NM_016103 
SAR1B 
SAR1 homolog B (S. 
cerevisiae) 
2.59 0.0262 
 
NM_004120 GBP2 
guanylate binding protein 2, 
interferon-inducible 
2.58 0.0142 
 NM_005516 HLA-E major histocompatibility 2.49 0.0078 
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complex, class I, E 
 
NM_001733 C1R 
complement component 1, r 
subcomponent 
2.23 0.0193 
 NM_018009 TAPBPL TAP binding protein-like 2.09 0.0305 
 
NM_024119 DHX58 
DEXH (Asp-Glu-X-His) box 
polypeptide 58 
2.02 0.0344 
 
NM_014494 TNRC6A 
trinucleotide repeat 
containing 6A 
2.02 0.0304 
 NM_001190986  
NM_006061 
CRISP3 
cysteine-rich secretory 
protein 3 
-4.70 0.0172 
 NM_001159587  
NM_001159588  
NM_133493 
CD109 CD109 molecule -3.10 0.0075 
 
NM_012199 EIF2C1 
eukaryotic translation 
initiation factor 2C, 1 
-2.44 0.0143 
 NM_001024843  
NM_001162501  
NM_015088 
TNRC6B 
trinucleotide repeat 
containing 6B 
-2.41 0.0162 
 NM_001206491  
NM_020746  
NR_037921 
MAVS 
mitochondrial antiviral 
signaling protein 
-2.34 0.0156 
 
NM_004157 PRKAR2A 
protein kinase, cAMP-
dependent, regulatory, type 
II, alpha 
-2.21 0.0074 
Regulation 
of gene 
expression 
(31 genes) 
NM_001199573  
NM_006074 
TRIM22 tripartite motif containing 22 17.62 0.0077 
NM_006084 IRF9 interferon regulatory factor 9 17.20 0.0032 
NM_001572  
NM_004029  
NM_004030  
NM_004031 
IRF7 interferon regulatory factor 7 8.27 0.0061 
 
NM_032789 PARP10 
poly (ADP-ribose) 
polymerase family, member 
10 
7.29 0.0052 
 NM_001185015  
NM_004509  
NM_004510  
NM_080424 
SP110 SP110 nuclear body protein 6.09 0.0022 
 
NM_001037335  
NM_033405 
PRIC285 
peroxisomal proliferator-
activated receptor A 
interacting complex 285 
4.94 0.0024 
 
NM_017554 PARP14 
poly (ADP-ribose) 
polymerase family, member 
14 
3.54 0.0040 
 
NM_004688 NMI 
N-myc (and STAT) 
interactor 
3.04 0.0024 
 NM_001008490  
NM_001160124  
KLF6 Kruppel-like factor 6 2.74 0.0053 
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NM_001160125  
NM_001300  
NR_027653 
 NM_014290 TDRD7 tudor domain containing 7 2.61 0.0024 
 NM_001040443  
NM_001040444  
NM_016119 
PHF11 PHD finger protein 11 2.41 0.0074 
 NM_001207035  
NM_001207036  
NM_001207037  
NM_001207038  
NM_001207039  
NM_001207040  
NM_001207041  
NM_016135 
ETV7 ets variant 7 2.31 0.0289 
 NM_001142467  
NM_021170 
HES4 
hairy and enhancer of split 4 
(Drosophila) 
2.17 0.0096 
 
NM_003709 KLF7 
Kruppel-like factor 7 
(ubiquitous) 
2.14 0.0171 
 
NM_005856 RAMP3 
receptor (G protein-coupled) 
activity modifying protein 3 
2.06 0.0269 
 NM_001170765  
NM_001170766  
NM_032440 
LCOR 
ligand dependent nuclear 
receptor corepressor 
2.00 0.0319 
 
NM_052966 FAM129A 
family with sequence 
similarity 129, member A 
-4.36 0.0118 
 NM_002197 ACO1 aconitase 1, soluble -3.42 0.0077 
 
NM_004096 EIF4EBP2 
eukaryotic translation 
initiation factor 4E binding 
protein 2 
-3.35 0.0040 
 
NM_015049 TRAK2 
trafficking protein, kinesin 
binding 2 
-2.75 0.0126 
 NM_001253379  
NM_001253380  
NM_001253382  
NM_001253383  
NM_001253384  
NM_002948 
RPL15 Ribosomal protein L15 -2.46 0.0240 
 NM_003251 THRSP thyroid hormone responsive -2.42 0.0358 
 NM_000977  
NM_001243130  
NM_001243131  
NM_033251  
NR_002450 
RPL13 
SNORD68 
ribosomal protein L13 
small nucleolar RNA, C/D 
box 68 
-2.32 0.0121 
 
NM_198182 GRHL1 
grainyhead-like 1 
(Drosophila) 
-2.26 0.0089 
 
NM_020459 PAIP2B 
poly(A) binding protein 
interacting protein 2B 
-2.20 0.0153 
 NM_000997  LOC1005065 uncharacterized -2.20 0.0258 
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NR_037665 48 
RPL37 
LOC100506548 
ribosomal protein L37 
 NM_001085471  
NM_005197 
FOXN3 forkhead box N3 -2.11 0.0145 
 NM_001114120  
NM_017779 
DEPDC1 DEP domain containing 1 -2.08 0.0137 
 NM_001145459  
NM_001145460  
NM_032495  
NM_139211  
NM_139212 
HOPX HOP homeobox -2.07 0.0176 
 
NM_144618 GABPB2 
GA binding protein 
transcription factor, beta 
subunit 2 
-2.01 0.0087 
 
NM_182762 MACC1 
metastasis associated in 
colon cancer 1 
-2.01 0.0257 
Unclassified 
(170 genes) 
NM_001256477  
NM_001256478  
NM_207315  
NR_046236 
CMPK2 
cytidine monophosphate 
(UMP-CMP) kinase 2, 
mitochondrial 
144.18 0.0256 
 
NM_022147 RTP4 
receptor (chemosensory) 
transporter protein 4 
56.51 0.0073 
 
NM_080657 RSAD2 
radical S-adenosyl 
methionine domain 
containing 2 
32.93 0.0090 
 NM_006674  
NR_040662 
HCP5 
HLA complex P5 (non-
protein coding) 
28.43 0.0083 
 
NM_003641 IFITM1 
interferon induced 
transmembrane protein 1 
24.55 0.0120 
 NM_001193307  
NM_017654 
SAMD9 
sterile alpha motif domain 
containing 9 
18.12 0.0024 
 
NM_172138 IL28A 
interleukin 28A (interferon, 
lambda 2) 
17.15 0.0084 
 
NM_152703 SAMD9L 
sterile alpha motif domain 
containing 9-like 
16.55 0.0098 
 NR_037173  
NR_037174  
NR_037175  
NR_037176 
LOC1005074
63 
uncharacterized 
LOC100507463 
13.44 0.0071 
 
NM_018381 C19orf66 
chromosome 19 open 
reading frame 66 
12.66 0.0052 
 
NM_017414 USP18 
ubiquitin specific peptidase 
18 
10.63 0.0024 
 
NM_022750 PARP12 
poly (ADP-ribose) 
polymerase family, member 
12 
9.10 0.0021 
 NM_001013000  
NM_001013002  
HERC6 HECT and RLD domain 
containing E3 ubiquitin 
8.60 0.0040 
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NM_001013005  
NM_001165136  
NM_017912 
protein ligase family member 
6 
 NM_005533 IFI35 interferon-induced protein 35 8.30 0.0024 
 NM_018295 TMEM140 transmembrane protein 140 6.84 0.0031 
 NM_030641 APOL6 apolipoprotein L, 6 6.48 0.0156 
 NM_001136540  
NM_001136541  
NM_003661  
NM_145343  
NM_145344 
APOL1 apolipoprotein L, 1 6.46 0.0049 
 NM_000110  
NM_001160301 
DPYD 
dihydropyrimidine 
dehydrogenase 
4.63 0.0124 
 NM_000110  
NM_001160301 
DPYD 
dihydropyrimidine 
dehydrogenase 
4.63 0.0124 
 NM_138287 DTX3L deltex 3-like (Drosophila) 4.25 0.0022 
 NM_001013717  
NM_001207001  
NM_001207002  
NM_001207003  
NR_045116 
C5orf56 
chromosome 5 open reading 
frame 56 
3.87 0.0068 
 NM_014668  
NM_033090  
NM_148903 
GREB1 
growth regulation by 
estrogen in breast cancer 1 
3.58 0.0285 
 
NM_014831 TRANK1 
tetratricopeptide repeat and 
ankyrin repeat containing 1 
3.45 0.0137 
 XR_109577  
XR_111839 
LOC1005075
35 
uncharacterized 
LOC100507535 
3.42 0.0061 
 NM_030882  
NM_145637 
APOL2 apolipoprotein L, 2 3.31 0.0092 
 NM_001114 ADCY7 adenylate cyclase 7 3.30 0.0076 
 NM_015907 LAP3 leucine aminopeptidase 3 3.14 0.0045 
 
NM_001161354  
NM_020904 
PLEKHA4 
pleckstrin homology domain 
containing, family A 
(phosphoinositide binding 
specific) member 4 
2.94 0.0257 
 NM_130808 CPNE4 copine IV 2.92 0.0162 
 
NR_024240 HLA-J 
major histocompatibility 
complex, class I, J 
(pseudogene) 
2.72 0.0032 
 NM_000826  
NM_001083619  
NM_001083620 
GRIA2 
glutamate receptor, 
ionotropic, AMPA 2 
2.70 0.0147 
 
NM_016479 SHISA5 
shisa homolog 5 (Xenopus 
laevis) 
2.69 0.0022 
 NM_031418 ANO3 anoctamin 3 2.63 0.0363 
 NM_001143781  FKBP11 FK506 binding protein 11, 2.59 0.0126 
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NM_001143782  
NM_016594 
19 kDa 
 
NM_021035 ZNFX1 
zinc finger, NFX1-type 
containing 1 
2.57 0.0127 
 
NM_006877 GMPR 
guanosine monophosphate 
reductase 
2.57 0.0377 
 NM_001127445  
NM_020361 
CPA6 carboxypeptidase A6 2.56 0.0320 
 NM_001256071  
NM_020914  
NM_020954 
RNF213 ring finger protein 213 2.50 0.0282 
 NM_018438 FBXO6 F-box protein 6 2.50 0.0045 
 NM_153610 CMYA5 cardiomyopathy associated 5 2.49 0.0337 
 
NM_001183 ATP6AP1 
ATPase, H+ transporting, 
lysosomal accessory protein 
1 
2.47 0.0069 
 
NM_001032392  
NM_002665  
NR_003506 
PLGLA 
PLGLB1 
PLGLB2 
plasminogen-like A 
plasminogen-like B1 
plasminogen-like B2 
2.41 0.0469 
 NM_001039210  
NM_001099922  
NM_001168385  
NM_001257230  
NM_001257231  
NM_001257234  
NM_001257235  
NM_001257237  
NM_001257239  
NM_001257240  
NM_001257241  
NM_018466  
NR_033124  
NR_033125  
NR_033127  
NR_033128 
ALG13 
asparagine-linked 
glycosylation 13 homolog 
(S. cerevisiae) 
2.39 0.0060 
 
NM_152400 C4orf32 
chromosome 4 open reading 
frame 32 
2.39 0.0313 
 
NM_020213  
NM_020214 
PARP6 
poly (ADP-ribose) 
polymerase family, member 
6 
2.38 0.0116 
 NM_016381  
NM_033627  
NM_033628  
NM_033629 
TREX1 
three prime repair 
exonuclease 1 
2.38 0.0063 
 NM_001204519  
NM_001204520  
NM_002561  
NM_175080  
NM_175081 
P2RX5 
purinergic receptor P2X, 
ligand-gated ion channel, 5 
2.38 0.0183 
Appendix 
115 
 
 
NM_198827 GPR133 
G protein-coupled receptor 
133 
2.33 0.0163 
 NM_004209 SYNGR3 synaptogyrin 3 2.33 0.0112 
 
NM_021071 ART4 
ADP-ribosyltransferase 4 
(Dombrock blood group) 
2.30 0.0333 
 
NM_001014440 ODF3B 
outer dense fiber of sperm 
tails 3B 
2.29 0.0177 
 NM_001100422  
NM_001100423  
NM_001100424  
NM_015535 
SPATS2L 
spermatogenesis associated, 
serine-rich 2-like 
2.22 0.0027 
 NM_021058 HIST1H2BJ histone cluster 1, H2bj 2.18 0.0478 
 
NM_014344 FJX1 
four jointed box 1 
(Drosophila) 
2.18 0.0108 
 
NM_006018 HCAR3 
hydroxycarboxylic acid 
receptor 3 
2.18 0.0227 
 NM_003649  
NM_004032 
DDO D-aspartate oxidase 2.18 0.0156 
 
NR_002801 PHF2P1 
PHD finger protein 2 
pseudogene 1 
2.17 0.0195 
 NM_001169109  
NM_001169110  
NM_001169111  
NM_005138 
SCO2 
SCO cytochrome oxidase 
deficient homolog 2 (yeast) 
2.17 0.0104 
 
NM_017633 FAM46A 
family with sequence 
similarity 46, member A 
2.17 0.0057 
 
XR_109952 
LOC1005073
07 
uncharacterized 
LOC100507307 
2.16 0.0089 
 NM_004866  
NM_052822 
SCAMP1 
secretory carrier membrane 
protein 1 
2.14 0.0209 
 
NM_014165 NDUFAF4 
NADH dehydrogenase 
(ubiquinone) complex I, 
assembly factor 4 
2.12 0.0330 
 
NM_001039954 MT1P2 
metallothionein 1 
pseudogene 2 
2.11 0.0085 
 
NM_144770 RBM11 
RNA binding motif protein 
11 
2.10 0.0465 
 NM_001252078  
NM_001252079  
NM_006313 
USP15 
ubiquitin specific peptidase 
15 
2.09 0.0089 
 
NM_152309 PIK3AP1 
phosphoinositide-3-kinase 
adaptor protein 1 
2.09 0.0059 
 NM_001003398  
NM_001714 
BICD1 
bicaudal D homolog 1 
(Drosophila) 
2.09 0.0440 
 NM_001002009  
NM_001002010  
NM_001166118  
NM_016489  
NT5C3 5'-nucleotidase, cytosolic III 2.08 0.0040 
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NR_029372 
 
NM_198562  
NR_036233 
C3orf62 
MIR4271 
chromosome 3 open reading 
frame 62 
microRNA 4271 
2.07 0.0267 
 
NM_013300 FAM216A 
family with sequence 
similarity 216, member A 
2.07 0.0031 
 NR_002819  
XR_110915  
XR_110916  
XR_110917  
XR_111190  
XR_111191  
XR_132900  
XR_132966 
LOC1005076
45 
MALAT1 
uncharacterized 
LOC100507645 
metastasis associated lung 
adenocarcinoma transcript 1 
(non-protein coding) 
2.06 0.0470 
 NM_001104558  
NM_024930 
ELOVL7 ELOVL fatty acid elongase 7 2.06 0.0053 
 NM_001126132  
NM_001126133  
NM_003283 
TNNT1 
troponin T type 1 (skeletal, 
slow) 
2.05 0.0144 
 NM_181718  
NM_198907 
ASPHD1 
aspartate beta-hydroxylase 
domain containing 1 
2.04 0.0283 
 
NM_004419 DUSP5 
dual specificity phosphatase 
5 
2.04 0.0382 
 
NM_001080414 CCDC88C 
coiled-coil domain 
containing 88C 
2.03 0.0108 
 
NM_001013698 C12orf69 
chromosome 12 open 
reading frame 69 
2.03 0.0229 
 NM_153029 N4BP1 NEDD4 binding protein 1 2.03 0.0177 
 NM_006462  
NM_031227  
NM_031228  
NM_031229 
RBCK1 
RanBP-type and C3HC4-
type zinc finger containing 1 
2.01 0.0052 
 
NM_017872 THG1L 
tRNA-histidine 
guanylyltransferase 1-like (S. 
cerevisiae) 
2.00 0.0075 
 NM_001165966  
NM_031220 
PITPNM3 PITPNM family member 3 -4.27 0.0118 
 
NM_017855 ODAM 
odontogenic, ameloblast 
asssociated 
-4.19 0.0257 
 
NM_004669 CLIC3 
chloride intracellular channel 
3 
-4.11 0.0087 
 NM_001242809  
NM_001242811  
NM_001242813  
NM_001242814  
NM_014942 
ANKRD6 ankyrin repeat domain 6 -4.04 0.0193 
 NM_001256310  
NM_014905 
GLS glutaminase -4.01 0.0059 
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 NM_182530  
XM_001716650  
XM_001718908 
C12orf28 
chromosome 12 open 
reading frame 28 
-3.65 0.0147 
 NM_020802 KIAA1377 KIAA1377 -3.64 0.0337 
 NM_001146265  
NM_001146266  
NM_001146267  
NM_018970 
GPR85 
G protein-coupled receptor 
85 
-3.43 0.0127 
 NM_001099  
NM_001134194 
ACPP acid phosphatase, prostate -3.40 0.0207 
 NM_030820 COL21A1 collagen, type XXI, alpha 1 -3.40 0.0235 
 
NM_015657  
NM_173076 
ABCA12 
ATP-binding cassette, sub-
family A (ABC1), member 
12 
-3.19 0.0153 
 NM_001121  
NM_016824  
NM_019903 
ADD3 adducin 3 (gamma) -3.13 0.0111 
 
NM_144695 BROX 
BRO1 domain and CAAX 
motif containing 
-3.01 0.0324 
 
NM_153456 HS6ST3 
heparan sulfate 6-O-
sulfotransferase 3 
-3.00 0.0080 
 
NM_001080472 FITM2 
fat storage-inducing 
transmembrane protein 2 
-2.83 0.0115 
 NM_001080975  
NM_004726 
REPS2 
RALBP1 associated Eps 
domain containing 2 
-2.82 0.0118 
 XR_108744  
XR_108745  
XR_108746  
XR_110646  
XR_110647  
XR_110648  
XR_112980  
XR_112981  
XR_112982 
LOC1005060
98 
uncharacterized 
LOC100506098 
-2.73 0.0104 
 NM_001136574  
NM_001136575  
NM_006055 
LANCL1 
LanC lantibiotic synthetase 
component C-like 1 
(bacterial) 
-2.68 0.0118 
 NM_173651  
NM_207482 
FSIP2 
fibrous sheath interacting 
protein 2 
-2.68 0.0096 
 NM_001167911  
NM_001167912  
NM_001167915  
NM_001167916  
NM_001167917  
NM_024621 
VEPH1 
ventricular zone expressed 
PH domain homolog 1 
(zebrafish) 
-2.67 0.0133 
 NM_001025777  
NM_020120  
NR_027671 
UGGT1 
UDP-glucose glycoprotein 
glucosyltransferase 1 
-2.63 0.0158 
 NR_024618 LOC1001295 uncharacterized -2.63 0.0291 
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50 LOC100129550 
 
NM_145740 GSTA1 
glutathione S-transferase 
alpha 1 
-2.55 0.0172 
 NM_014033 METTL7A methyltransferase like 7A -2.55 0.0417 
 
NM_001204827  
NM_022098 
XPNPEP3 
X-prolyl aminopeptidase 
(aminopeptidase P) 3, 
putative 
-2.48 0.0254 
 XR_109447  
XR_111683 
LOC1005064
18 
uncharacterized 
LOC100506418 
-2.47 0.0220 
 NM_001142314  
NM_080876 
DUSP19 
dual specificity phosphatase 
19 
-2.47 0.0390 
 NM_012412  
NM_138635  
NM_201436  
NM_201516  
NM_201517 
H2AFV 
H2A histone family, member 
V 
-2.47 0.0114 
 NM_001145304  
NM_001145305  
NM_025249 
KIAA1683 KIAA1683 -2.45 0.0225 
 NM_001129896  
NM_001174068  
NM_080737 
SYTL4 synaptotagmin-like 4 -2.43 0.0061 
 NM_001039547  
NM_152776  
NR_033289 
GK5 glycerol kinase 5 (putative) -2.41 0.0357 
 
NR_003020  
NR_003142 
SNHG9 
SNORA78 
small nucleolar RNA host 
gene 9 (non-protein coding) 
small nucleolar RNA, 
H/ACA box 78 
-2.40 0.0049 
 NM_001171109  
NM_001171110  
NM_001171111  
NM_173698 
FAM133A 
family with sequence 
similarity 133, member A 
-2.37 0.0145 
 
XR_110942 
LOC1002890
26 
uncharacterized 
LOC100289026 
-2.36 0.0454 
 
NM_198859 PRICKLE2 
prickle homolog 2 
(Drosophila) 
-2.35 0.0028 
 NM_022766  
NM_182661 
CERK ceramide kinase -2.35 0.0040 
 XR_108636  
XR_108637  
XR_112864  
XR_112865 
LOC1001316
07 
uncharacterized 
LOC100131607 
-2.33 0.0269 
 
NM_024963 FBXL18 
F-box and leucine-rich repeat 
protein 18 
-2.31 0.0085 
 NM_004058  
NM_080590 
CAPS calcyphosine -2.31 0.0196 
 NM_004980  KCND3 potassium voltage-gated -2.30 0.0103 
Appendix 
119 
 
NM_172198 channel, Shal-related 
subfamily, member 3 
 NM_001142386  
NM_005391 
PDK3 
pyruvate dehydrogenase 
kinase, isozyme 3 
-2.28 0.0215 
 NM_001039538  
NM_002374  
NM_031845  
NM_031846  
NM_031847 
MAP2 
microtubule-associated 
protein 2 
-2.28 0.0174 
 NM_001178106  
NM_001178107  
NM_001178108  
NM_001178109  
NM_001178110  
NM_001178113  
NM_001178114  
NM_001178115  
NM_007150 
ZNF185 
zinc finger protein 185 (LIM 
domain) 
-2.27 0.0255 
 NM_001252335  
NM_032866 
CGNL1 cingulin-like 1 -2.26 0.0102 
 
NM_003979 GPRC5A 
G protein-coupled receptor, 
family C, group 5, member 
A 
-2.25 0.0093 
 NM_080626 BRI3BP BRI3 binding protein -2.23 0.0061 
 
NM_145244 DDIT4L 
DNA-damage-inducible 
transcript 4-like 
-2.22 0.0216 
 NM_000293  
NM_001031835 
PHKB phosphorylase kinase, beta -2.22 0.0151 
 NM_001242318  
NM_002603  
NM_002604 
PDE7A phosphodiesterase 7A -2.21 0.0074 
 
NR_027420 LOC389834 
ankyrin repeat domain 57 
pseudogene 
-2.21 0.0277 
 XR_110055  
XR_110056  
XR_112635  
XR_112636 
USP46-AS1 
USP46 antisense RNA 1 
(non-protein coding) 
-2.21 0.0408 
 NM_175898  
NR_028330 
C15orf37 
chromosome 15 open 
reading frame 37 
-2.21 0.0220 
 NM_173582 PGM2L1 phosphoglucomutase 2-like 1 -2.20 0.0061 
 NM_144665 SESN3 sestrin 3 -2.20 0.0459 
 
NM_006517 SLC16A2 
solute carrier family 16, 
member 2 (thyroid hormone 
transporter) 
-2.20 0.0077 
 NM_017698  
NM_032227 
TMEM164 transmembrane protein 164 -2.19 0.0135 
 XR_109253  
XR_111639 
LOC1005054
87 
uncharacterized 
LOC100505487 
-2.19 0.0198 
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NM_015962 FCF1 
FCF1 small subunit (SSU) 
processome component 
homolog (S. cerevisiae) 
-2.19 0.0308 
 NM_001136032  
NM_001167605  
NM_006853  
NM_144947 
KLK11 
kallikrein-related peptidase 
11 
-2.19 0.0057 
 NM_016348  
NM_032385 
C5orf4 
chromosome 5 open reading 
frame 4 
-2.18 0.0077 
 
NM_001032281  
NM_006287 
TFPI 
tissue factor pathway 
inhibitor (lipoprotein-
associated coagulation 
inhibitor) 
-2.17 0.0409 
 NM_021992  
NM_194324 
TMSB15A 
TMSB15B 
thymosin beta 15a 
thymosin beta 15B 
-2.15 0.0084 
 NM_001170701  
NM_001170702  
NM_001170703  
NM_001170704  
NM_018388  
NM_133486 
MBNL3 
muscleblind-like splicing 
regulator 3 
-2.14 0.0138 
 
NM_004126 GNG11 
guanine nucleotide binding 
protein (G protein), gamma 
11 
-2.14 0.0447 
 NM_001201573  
NM_001201574  
NM_025152 
NUBPL 
nucleotide binding protein-
like 
-2.13 0.0452 
 NM_001206840  
NM_001206841  
NM_001206844  
NM_006464 
TGOLN2 trans-golgi network protein 2 -2.13 0.0127 
 NM_152350  
NR_002744  
NR_003043  
NR_003054  
NR_027158  
NR_027159  
NR_027160  
NR_027161  
NR_027162  
NR_027163  
NR_027164  
NR_027165  
NR_027166  
NR_027167  
NR_027168  
NR_027169  
NR_027170  
NR_027171 
C17orf76-
AS1 
SNORD49A 
SNORD49B 
SNORD65 
C17orf76 antisense RNA 1 
(non-protein coding) 
small nucleolar RNA, C/D 
box 49A 
small nucleolar RNA, C/D 
box 49B 
small nucleolar RNA, C/D 
box 65 
-2.13 0.0118 
 NM_001145666  
NM_001145667  
NM_012201  
GLG1 golgi glycoprotein 1 -2.11 0.0022 
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NR_027264  
NR_027265 
 NM_182487 OLFML2A olfactomedin-like 2A -2.11 0.0321 
 
NM_003818 CDS2 
CDP-diacylglycerol synthase 
(phosphatidate 
cytidylyltransferase) 2 
-2.10 0.0292 
 
NM_012164 FBXW2 
F-box and WD repeat 
domain containing 2 
-2.10 0.0212 
 NM_019598  
NM_145894  
NM_145895 
KLK12 
kallikrein-related peptidase 
12 
-2.09 0.0050 
 NM_001199505  
NM_001199506  
NM_080672  
NM_183244  
NM_183246 
PHACTR3 
phosphatase and actin 
regulator 3 
-2.09 0.0271 
 NM_020632  
NM_130840  
NM_130841 
ATP6V0A4 
ATPase, H+ transporting, 
lysosomal V0 subunit a4 
-2.08 0.0418 
 
NM_004863 SPTLC2 
serine palmitoyltransferase, 
long chain base subunit 2 
-2.08 0.0353 
 NM_174909 TMEM167A transmembrane protein 167A -2.08 0.0111 
 
NM_001134456  
NM_145037 
NXPE3 
neurexophilin and PC-
esterase domain family, 
member 3 
-2.08 0.0416 
 
NM_002898 RBMS2 
RNA binding motif, single 
stranded interacting protein 2 
-2.08 0.0184 
 
NM_152766 C17orf61 
chromosome 17 open 
reading frame 61 
-2.07 0.0115 
 
XR_133136 
LOC1006533
29 
uncharacterized 
LOC100653329 
-2.06 0.0185 
 NM_001031693  
NM_001036645  
NM_001036646  
NM_007071  
NR_027404 
HHLA3 HERV-H LTR-associating 3 -2.05 0.0183 
 NM_001042459  
NM_014890  
NM_182909 
FILIP1L 
filamin A interacting protein 
1-like 
-2.05 0.0052 
 NR_039871 MIR4720 microRNA 4720 -2.04 0.0095 
 
NM_001013620 ALG10B 
asparagine-linked 
glycosylation 10, alpha-1,2-
glucosyltransferase homolog 
B (yeast) 
-2.04 0.0372 
 
NM_014058 TMPRSS11E 
transmembrane protease, 
serine 11E 
-2.03 0.0101 
 NM_030650 KIAA1715 KIAA1715 -2.03 0.0191 
 NM_001010911 C10orf114 chromosome 10 open -2.03 0.0476 
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reading frame 114 
 NM_139248 LIPH lipase, member H -2.01 0.0317 
 
NM_002867 RAB3B 
RAB3B, member RAS 
oncogene family 
-2.01 0.0199 
 NM_152375 KLHDC7A kelch domain containing 7A -2.01 0.0347 
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